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The kidney
 The kidney (Figure 1) is a bean-shaped organ that consists of two 
distinct regions; the outer cortex and the medulla. The kidney contains 
more than a million functional units, the so-called nephrons. Nephrons 
consist of glomeruli and tubules, and are responsible for the glomerular 
ultrafi ltration process and the reabsorption of ions and water. The 
glomeruli are located in the cortex and the tubular part is located in both 
the cortex and the medulla. The tubular part of the nephron is in continuum 
with Bowman’s capsule surrounding the glomerular tuft and receives the 
primary glomerular fi ltrate. The tubular system consists of the proximal 
convolute and straight tubule, the descending and ascending thin limbs 
of the loop of Henle, the distal straight and convoluted tubule and the 
connecting tubule, which connects the nephron to the collecting ducts. 
 The glomerulus is composed of a capillary network encapsulated 
by Bowman’s capsule, which is lined with a layer of glomerular parietal 
epithelial cells (GPECs). The glomerular capillary wall consists of a single 
layer of fenestrated endothelial cells covering the glomerular basement 
membrane (GBM). These glomerular endothelial cells are characterized 
by the presence of numerous non-diaphragmed fenestrae of about 100 
nm in diameter in humans1. The GBM is covered at the opposite (urinary) 
side with visceral epithelial cells, called podocytes. The supporting 
mesangial cells (MCs) lie in between the microcapillaries. MCs are a type 
of myofi broblasts, which support the glomerular tuft and regulate the 
capillary diameter and blood fl ow. These cells have similarities to vascular 
smooth muscle cells (e.g. contractility), can proliferate and are phagocytic. 
Furthermore, MCs produce various growth factors, cytokines, chemokines 
and adhesion factors. Due to their phagocytic capabilities, MCs are 
involved in the handling of various macromolecules, such as lipids and 
immune complexes. The glomerulus contains three extracellular matrices 
(ECMs), the mesangial matrix, Bowman’s capsule matrix and the GBM. 
Under normal conditions the mesangial matrix consists of type IV, V and 
VI collagens with laminins, fi bronectin, entactin and proteoglycans (PGs). 
The GBM in humans is normally 310-380 nm thick and is composed of type 
IV collagens, laminins, nidogen, fi bronectin and PGs2. Bowman’s capsule 
matrix mainly consists of type IV collagen and also comprises PGs. 
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Figure 1. Artistic impression of the kidney. The kidney is a bean-shaped organ that 
consists of two distinct regions; the outer cortex and the medulla. The kidney consists of 
more than a million functional units, the nephrons. These nephrons consist of glomeruli and 
tubules. The glomeruli are located in the cortex and the tubular part is located in both the 
cortex and the medulla. The tubular system consists of the proximal convolute and straight 
tubule, the descending and ascending thin limbs of the loop of Henle, the distal straight and 
convoluted tubule and the connecting tubule, which connects the nephron to the collecting 
ducts. These collecting ducts connect to the pelvis, witch connects to the urether. (picture 
by courtesy of John Turnier © 2011)
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Proteoglycans and glycosaminoglycans
Proteoglycans (PGs) consist of a core protein with one or more 
glycosaminoglycan (GAG) side chains covalently att ached3. GAGs are 
linear polysaccharides consisting of repeating disaccharide units and 
are produced in virtually every cell of the human body. They are either 
secreted into the extracellular matrix or retained at the cell surface. 
GAGs bind a myriad of factors and thereby mediate many biological 
processes like cell growth, cell diﬀ erentiation, signal transduction and cell 
adhesion4;5. Numerous factors, including growth factors, cytokines and 
chemokines bind to GAGs. The binding of factors to GAGs as co-receptor 
is important for their immobilization and gradient formation, which 
enhances the binding to their actual receptors. The binding of factors to 
GAGs may induce conformational changes either in the GAG chain or 
the GAG-binding factor itself, which could have functional consequences 
for receptor triggering. GAGs also may function as sink for GAG-binding 
factors in the ECM or in protection against degradation of GAG-binding 
factors by for example proteases.
The major GAG classes include heparan sulfate/heparin (HS/
hep), keratan sulfate (KS), dermatan sulfate (DS) and chondroitin sulfate 
(CS). The various GAG classes diﬀ er in the composition of their basic 
disaccharide unit. GAGs can be divided into the glucosaminoglycans 
(Figure 2A) and the galactosaminoglycans (Figure 2B). KS, HS and heparin 
belong to the glucosaminoglycans. KS consists of repeating disaccharide 
units of GlcNAc and galactose and can be sulfated at the C6 position of 
both residues. HS consists of repeating disaccharide units consisting of a 
GlcNAc and a uronic acid (UA) residue, the latt er can be either a GlcA or 
can be epimerized by the C5-epimerase to form IdoA. The UA residue can 
be sulfated at the C2 position (2-O-sulfation, 2S). The glucosamine residue 
are N-acetylated (NAc), N-sulfated (NS), or N-unsubstituted (NH2), and 
may be sulfated at the C3 (3-O-sulfation, 3S) and C6 (6-O-sulfation, 6S) 
positions (Figure 2A). Heparin is similar to HS, but has a higher degree of 
sulfation, usually more than 70% compared to less than 50% sulfation of 
HS, and heparin has a higher degree of C5-epimerization. CS and DS belong 
to the galactosaminoglycans. CS consists of repeating disaccharide units of 
N-acetyl-D-galactosamine (GalNAc) and D-glucuronic acid (GlcA). The CS/
DS disaccharide unit can be modifi ed as depicted in fi gure 2B by sulfation 
at the C4 (chondroitin-4-sulfate, CSA), the C6 (chondroitin-6-sulfate, CSC) 
and at both the C4 and C6 (chondroitin-4,6-sulfate, CSE) positions of the 
hexosamine unit. DS is also referred to as chondroitin sulfate-B (CSB), and 
only diﬀ ers from CS by the (partial) epimerization of GlcA to L-iduronic 
Chapter 1
12
Figure 2. Disaccharide composition of the diﬀ erent glycosaminoglycans and the diﬀ erent 
enzymes involved in the modifi cation steps. a) represents heparan sulfate, b) represents 
dermatan (left) and chondroitin (right) sulfate. The disaccharide units can all be diﬀ erent in 
their sulfate and iduronic acid composition. Furthermore, a GAG chain can consist of more 
than 150 disaccharide units. (A) HS consists of repeating disaccharide units comprising 
of a N-acetyl-glucosamine (GlcNAc) and a uronic acid (UA) residue. The glucosamine 
residue can be modifi ed by N-deacetylation/N-sulfation. GlcA can be epimerized by the C5-
epimerase to form IdoA. The GlcA/IdoA residue can be sulfated at the C2 position and the 
glucosamine residue can be sulfated at the C3 and C6 positions. (B) DS and CS consist of 
repeating disaccharide units of N-acetyl-D-galactosamine (GalNAc) and D-glucuronic acid 
(GlcA). DS can be (partially) epimerized by C5-epimerase. The DS disaccharide unit can be 
modifi ed by sulfation at the C4 (D4ST) position and at C2 (CS/DS2ST) of L-iduronic acid. 
The CS disaccharide unit can be sulfated at C4 and/or C6 of GalNAc. Subsequently, the 
6-O-sulfated GalNAc-GlcA can be sulfated at C2 of GlcA. Reprinted with permission from 
Elsevier from 106.
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acid (IdoA). This IdoA in turn can be modifi ed by sulfation at the C2 
position (Figure 2B)6. Hyaluronic acid (HA) also belongs to the GAG 
family and is the only GAG that is not linked to a core protein and that is 
non-sulfated. HA consists of repeating N-acetyl-D-glucosamine (GlcNAc) 
and D-glucuronic acid (GlcA) disaccharide units, which can mount up to 
several thousands.
The series of possible modifi cations of the GAG polysaccharide 
results in a very complex structure7. For CS and DS 24 diﬀ erent modifi cation 
are possible, and for HS there are even 48 possibilities8. With combinations 
of these disaccharides in an average GAG chain of more than 150 
disaccharide units a huge number of structural diﬀ erent GAG chains can 
be generated, each with unique disaccharide sequences. This complexity is 
even increased since one core protein can hold more than one GAG chain, 
which is not necessarily restricted to one specifi c GAG class7;9.
Renal proteoglycans
In the kidney HS, DS and CS is present, whereas KS seems absent. 
A number of diﬀ erent HS disaccharides have been found, including GlcA-
GlcNR (R can be an acetyl or a sulfate group), IdoA-GlcNR, GlcA2S-GlcNR, 
IdoA2S-GlcNR, GlcA-GlcNR6S, IdoA-GlcNR6S and IdoA2S-GlcNR6S10-13. 
Furthermore, GlcNH2-containing disaccharides are also present in the 
kidney, and account for about 2% of the total disaccharide units14. In 
addition to HS, a number of diﬀ erent DS and CS domains have been 
detected in the kidney, including a 2,4-di-O-sulfated and a 4-O-sulfated 
domains15 and 4-, 6-, and 4,6-O-sulfated CS domains16.
The diﬀ erent types of PGs present in the kidney are specifi cally located 
either on the cell surface or in the ECM. Some of these PGs have a HS chain 
att ached (HSPG), some CS/DS (CS/DSPG) and others can combine HS and 
CS/DS side chains (Table 1)17-21.
ECM and fi brosis/sclerosis
The ECM is an organized extracellular structure composed of PGs, 
collagens, elastin, fi brillin, adhesion molecules like fi bronectin and laminin, 
and diﬀ erent types of metalloproteinases (MMPs), all playing important 
roles in cell signalling and cellular functions22. 
In response to injurious stimuli tissues initially undergo a cascade of 
events in an att empt to repair, heal, and recover from the damage. Wound-
healing processes include production and secretion of chemokines and 
cytokines, recruitment of infl ammatory cells to the injured sites, activation 
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of fi broblasts to produce ECM, regeneration of damaged tissue through cell 
proliferation and diﬀ erentiation, and fi nally result in matrix remodelling. 
Various cytokines, chemokines and growth factors are able to 
induce proliferation and activation of mesenchymal cells including renal, 
dermal and lung fi broblasts. Furthermore, the secreted factors are able to 
stimulate epithelial cells, such as renal tubular epithelial cells, to undergo 
epithelial to mesenchymal transformation (EMT) allowing transformation 
to myofi broblasts23-25.
Table 1. The localization of the diﬀ erent types of PGs in the kidney
GAG, glycosaminoglycan; SLRP, small-leucine rich proteoglycans; GBM, glomerular 
basement membrane; BC, Bowman’s capsule; Mes., mesangium; Tub., tubules; Vasc., 
vasculature; MC, mesangial cell; Podo, podocyte; GEC, glomerular endothelial cell; HS, 
heparan sulfate; CS, chondroitin sulfate; DS, dermatan sulfate; KS, keratan sulfate.
References: 1;17;19;21;58-60;107-120
Chronic injurious stimuli lead to an imbalance in the synthesis 
and degradation of ECM components, characterized by an excessive rate 
of synthesis and accumulation of matrix and/or decreased degradation 
of ECM, ultimately leading to fi brotic lesions and tissue scarring. During 
the scarring process at fi rst, immature poorly collagenized fi brous tissue 
is deposited, which subsequently is substituted by collagenized mature 
connective tissue, thus forming a scar26;27. The ECM produced during 
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fi brogenesis is enriched for PGs and their GAG side chains, like HS, CS 
and DS, indicating a role for these GAGs in the fi brotic process.
 
 A well studied organ with regard to fi brosis is the kidney. 
Irrespective of the initial cause, progressive chronic kidney disease (CKD) 
often results in widespread tissue scarring, characterized by an excessive 
accumulation and deposition of ECM components, ultimately leading to 
end-stage renal disease (ESRD)28;29. There are a number of diﬀ erent causes 
that can lead to the progression of fi brosis including, glomerulonephritis, 
diabetes mellitus, hypertension, tubulointerstitial nephritis, renal 
obstruction, proteinuria and chronic transplant rejection. The hallmark of 
renal fi brosis is the excessive deposition of ECM consisting of fi brillar and 
basement membrane collagens type I, III and IV, and of HS and CS/DS PGs.
 Renal fi brosis can be distinguished in glomerulosclerosis and 
tubulointerstitial fi brosis. In both forms activation of matrix producing 
cells is generally regarded as a central event. The major fi brogenic cells in 
the glomerulus are mesangial cells, whereas in the tubular compartment 
interstitial fi broblasts and tubular epithelial cells are key fi brogenic cells. 
Close interaction between the fi brogenic cells is necessary for initiation and 
progression of renal fi brosis28;30
In glomerular fi brosis the matrix producing mesangial cells are the central 
cells, although glomerular endothelial and epithelial cells (podocytes and 
parietal epithelial cells) can play a role in excessive ECM production as 
well. Injury to the glomerular cells and subsequent activation leads to an 
infl ammatory process att racting infl ammatory cells that will interact with 
the resident glomerular cells31-33. The release of a wide range of chemokines, 
cytokines and growth factors, such as TGF-β, CTGF, platelet-derived 
growth factor (PDGF), FGF-2 and IL-1 & -634;35, att ract infl ammatory 
cells, which are capable to stimulate ECM production by activation of 
mesangial cells30;31;36. These activated mesangial cells are able to produce 
a large amount of ECM, which leads to mesangial matrix expansion37 and 
ultimately to glomerulosclerosis31;38.
 Tubulointerstitial damage can be either the primary cause for renal 
damage, like in chronic tubulointerstitial nephritis, or it occurs secondary 
to glomerular diseases31. Released factors are capable of activating and 
stimulating the proliferation of interstitial fi broblasts into myofi broblasts 
leading to the production of ECM. In addition, tubular epithelial cells can 
be triggered by the released factors to transform into myofi broblasts39;40. 
The deposition of type I collagen further promotes EMT41. Besides resident 
interstitial fi broblasts and EMT-derived fi broblasts, interstitial fi broblasts 
Chapter 1
16
may derive from circulating fi brocytes, bone marrow-derived fi broblasts, 
and myofi broblasts31;42;43. The formed myofi broblasts produce excessive 
amounts of ECM, which ultimately leads to interstitial fi brosis. Continuous 
injury, infl ammation, and fi broblast activation and proliferation will 
ultimately lead to irreversible fi brosis40.
 PG core proteins and GAGs have been implicated in many of the 
crucial steps associated with renal fi brosis, including the control of collagen 
deposition, fi bril formation, and regulation of growth factors and cytokines. 
Expression of specifi c PG and GAG may be either up-regulated or down-
regulated in numerous fi brotic diseases, including renal diseases. Current 
therapies for renal fi brosis, i.e. treatment with immunosuppressive drugs, 
also aﬀ ect PG expression, like versican44, decorin (DCN) and biglycan 
(BGN)45. 
Alterations of PG core proteins and GAGs in experimental and human renal 
disease
Alterations in PG core protein and GAG side chain expression 
and composition have been observed in a wide variety of renal diseases 
in humans, including diabetic nephropathy, Denys-Drash syndrome, 
forms of primary glomerulonephritis, hypertensive nephrosclerosis, and 
amyloidosis46-50.  It has been shown that altered expression of PGs and GAGs 
correlates with loss of renal function, suggesting an important (patho)
physiological role in the progression of renal failure51. The importance of 
PGs and GAG-modifying enzymes for normal renal physiology is further 
underscored in several PG/GAG knockout mouse models that develop a 
renal phenotype52-56.
 There is much less known about CS/DS compared to HS in these 
processes. In the embryonic kidney these CS/DS GAGs account for 
approximately 75% of the GAGs57, indicating an important role in renal 
development. In fi brosis many processes seem to occur that involve 
a regression to the embryonic stage, like EMT and an increased CS 
expression17;58-60. CS/DSPGs seem to play an important role in fi brosis, since 
most of the CS/DSPGs, especially DCN and BGN, are known to co-localize 
with myofi broblasts and ECM components, especially collagens61;62. In 
diseases presenting with fi brosis, including isolated diﬀ use mesangial 
sclerosis (IDMS), Denys-Drash syndrome (DDS) and diabetic nephropathy, 
a general decrease in HS and HSPG expression has been determined46;63-65, 
sometimes with an additional decrease in N-sulfation of HS49. In some 
patients with decreased HSPG expression an increased glomerular CS 
and CSPG expression was found, even before an increase in other ECM 
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proteins was noticed46;65. Furthermore, in glomerular nephropathies, 
including diabetic nephropathy, mesangial sclerosis and nephrosclerosis, 
an up-regulation of the CS/DSPGs DCN and BGN often together with type 
I collagen has been found62;66;67. This increase in CS/DS content sometimes, 
like in tubulointerstitial nephritis, is accompanied by a decrease in the 
degree of sulfation and a decrease in the IdoA content68. This increase in 
matrix components like collagen, CS, DS, and CS/DSPG’s is also seen in 
experimental renal disease models, like diabetes, subtotal nephrectomy and 
unilateral uretheral obstruction51;69-74. Studies also suggest a protective role 
of decorin in the development of diabetic nephropathy75. The importance 
of CS and DS is further shown in mesangial cells and podocytes in diabetic 
nephropathy, where it seems that a decreased HS synthesis and sulfation 
is accompanied with an increase in total GAG content, which could be 
due to an increased DS expression and synthesis, whereas HSPG core 
expression is not altered76-78. In a recent study, however, a decrease in renal 
CS/DS content was observed in experimental diabetic nephropathy79. An 
increase in CS/DSPG and HSPG expression by renal cells is observed after 
stimulation with the pro-fi brotic factor TGF-β80;81, whereas the GAGs show 
an increased sulfation and chain length82-84. Notably, GAGs can infl uence 
the bioactivity of TGF-β after binding, which suggest a continuous interplay 
between TGF-β activity and alterations in GAG amount and composition. 
Treatment of mesangial cells with heparin or DS, inhibits TGF-β1 mRNA 
expression and bioactive TGF-β1 protein expression85. A decrease in 
TGF-β1 mRNA expression is also observed in human mesangial cells 
overexpressing the DSPG DCN86. In general, there seems to be an increase 
in CS/DS in fi brosis. The up-regulation of CS/DS expression observed in 
several in vitro studies, experimental models and human renal diseases 
might be related to the DS dependence of fi broblasts for their migration into 
the ECM87. In this way, the up-regulation of CS/DS expression facilitates 
the infl ux of fi broblasts into injured areas. Another explanation is that the 
increase in DS size, for instance observed early in wound healing, is used 
by the body to control collagen fi bril formation and organization88. Further 
organization of fi brillar networks is also controlled by the CS/DSPGs DCN 
and BGN as demonstrated in DCN -/- and BGN -/- mice89;90.
Overall, GAGs and PGs have been linked to many processes 
involved in fi brosis, either by infl uencing cell movement, ECM organization 
or by binding growth factors that are actively involved. This oﬀ ers the 
possibility to further investigate the therapeutic potential of these intriguing 
molecules. To fully understand the roles of GAGs and PGs in renal fi brosis/
sclerosis, additional research is needed with focus on CS/DSPGs and their 
role in this process. 
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Antibody phage display / scFv antibodies
 Antibodies are widely used as tools to investigate specifi c antigens 
and also as therapeutic tools. Most of the available antibodies are directed 
against the core protein of proteoglycans. Only a few antibodies that are 
reactive with the GAG moiety have been described91-95. However, these 
were all generated using proteoglycans rather than isolated GAGs. Because 
of the non-immunogenic nature of the GAG chains, a special approach has 
been developed, the antibody phage display technique. This technique uses 
M13 bacteriophages to express random single chain antibody fragments 
(scFv) fused to their coat proteins96;97. A phage display library contains 
millions of diﬀ erent phages each displaying a unique antibody. Phage 
display libraries allow for the selection of antibodies directed against 
self-antigens, which is highly benefi cial because it circumvents the non-
immunogenic nature of GAGs. 
 Phage display technology also allows for genetic engineering of 
human antibody-derived phage libraries, which allows use in the clinical 
sett ing. During antibody selection, the target molecule can be immobilized 
to test tube walls and the phage library (displaying ~108-109 diﬀ erent 
antibodies) can be added and allowed to bind to the target molecule. 
The strongest binding phages, displaying the most specifi c antibodies 
to the target molecule, can then be eluted and further amplifi ed. Using 
this technique92, a large panel of specifi c antibodies against HS, heparin, 
CS, and DS, which recognize specifi c modifi cation patt erns have already 
been generated in our lab16;98-101. Two specifi c anti-DS antibodies have 
been described so far, antibody 2A12 that specifi cally reacts with 2,6-di-
O-sulfated DS from Ascidia nigra91 and scFv antibody GD3A12, which 
especially reacts with 4-O-sulfated DS15.
 A variety of anti-GAG antibodies have been used to study the 
distribution of GAG domains in diﬀ erent organs, like the spleen102, lung103 
and skeletal muscle104. The endogenous expression of anti-HS antibodies 
resulted in the functional knockout of specifi c HS domains, which was 
shown to interfere with ion housekeeping in skeletal muscle cells105. 
Furthermore, the functional properties of the HS domains can be analyzed 
by competition ELISA using a given anti-HS antibody and e.g. FGF-2. 
This provides essential knowledge on the functional properties of a HS 
domain and gives the possibility to interfere with the binding of a specifi c 
factor98. The usage of the antibody phage-display technique allows further 
elucidation of the location and function of diﬀ erent GAG domains in the 
kidney. 
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Scope and outline of the thesis
In PG research litt le is known about the GAG moieties, especially 
with respect to their role in renal (patho)physiology. This is likely due to 
a lack of appropriate tools to study the domain structure of GAGs. The 
overall aim of this thesis was to evaluate the role of GAGs and in particular 
specifi c GAG domains, in renal (patho)physiology, with a focus on DS 
using the phage display technology to obtain specifi c anti-DS antibodies. 
In Chapter 1 an overview of the role of PG core proteins and GAG 
side chains in renal sclerosis and fi brosis is given. In addition, a short 
introduction to the phage display technology is presented. Phage display 
technology can be used to select scFv antibodies directed against specifi c 
GAG domains. In Chapter 2, the phage display technology is further 
detailed with respect to the selection of specifi c scFv antibodies against 
GAG domains. In Chapter 3 a panel of anti-GAG scFv antibodies, i.e. 
anti-HS and anti-CS antibodies, is used to defi ne the topology of specifi c 
GAG domains in the normal human kidney. To gain more insight into the 
functional aspects of GAG domains, one of the domains, defi ned by the 
anti-HS antibody HS4C3, is studied in more detail in an in vitro cell model 
using mesangial cells. In many (fi brotic) diseases there is an increase in 
extracellular matrix, accompanied by an increase in DS. Since there were 
no specifi c anti-DS antibodies, the phage display technique was applied 
to obtain them. In Chapter 4 the selection and initial characterization of a 
unique anti-DS antibody is described. In the next chapter, Chapter 5, the 
use of this antibody together with another phage display-derived anti-DS 
antibody is described in the evaluation of the distribution and dynamics of 
DS domains in renal transplant rejections and a panel of other glomerular 
pathologies. In Chapter 6, an alternative approach to obtain phage display-
derived scFv antibodies, the in vivo phage display technique, is described. 
This technique may be used to select antibodies specifi c for GAG epitopes 
that are located at the luminal side of the blood vessels. Finally, in Chapter 
7 and Chapter 8 the fi ndings are summarized and perspectives for future 
research are given.
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Abstract
Glycosaminoglycans (GAGs) are long unbranched polysaccharides, most of 
which are linked to a core protein to form proteoglycans. Depending on the 
nature of their backbone, one can discern galactosaminoglycans (chondroitin 
sulfate (CS), and dermatan sulfate (DS)) and glucosaminoglycans (heparan 
sulfate (HS), heparin, hyaluronic acid, and keratan sulfate). Modifi cation 
of the backbone by sulfation, deacetylation, and epimerization results in 
unique sequences within GAG molecules which are instrumental in the 
binding of a large number of proteins. Investigating the exact roles of 
GAGs has long been hampered by the lack of appropriate tools. In recent 
years, we have successfully implemented phage display technology 
to generate a large panel of antibodies against CS, DS, HS, and heparin 
epitopes. These antibodies provide unique and highly versatile tools to 
study the topography, structure and function of specifi c GAG domains. In 
this chapter, we describe the selection, characterization, and application of 
antibodies against specifi c GAG epitopes. 
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Overview
Antibodies are widely used in the research on proteoglycans. They have 
been applied to evaluate proteoglycan expression patt erns in a variety 
of tissues in health and disease, and have also been used as (immuno) 
precipitating agents. Most of the antibodies available to date are directed 
against the core protein of proteoglycans. Only a few antibodies that are 
reactive with the glycosaminoglycan (GAG) moiety have been described 
1- 5. However, these were all generated using proteoglycans rather than 
isolated GAGs. 
Investigating the biological role of GAGs has long been hampered by 
the lack of appropriate tools. Using phage display technology we have 
generated a large panel of epitope-specifi c antibodies against heparan 
sulfate (HS), heparin, chondroitin sulfate (CS), and dermatan sulfate (DS)6- 
10 (Table I). Characterization of the GAGs bound by the antibodies revealed 
that specifi c modifi cation patt erns are recognized10, 11. For instance, one 
specifi c antibody against HS requires 3-O sulfates and recognizes an epitope 
that resembles the antithrombin-III binding pentasaccharide sequence12. A 
variety of anti-GAG antibodies was used to study the distribution of GAG 
epitopes in spleen13, lung14, kidney15, and skeletal muscle16. GAG-specifi c 
antibodies were also used to study changes in expression patt ern in 
diseased versus healthy tissue, especially melanoma and psoriasis8, 17. Next 
to immunohistochemical evaluation, antibodies were applied to analyze the 
biological function of GAGs e.g. growth factor binding. The endogenous 
expression of anti-HS antibodies resulted in the functional knock-out of 
specifi c HS epitopes, which was shown to interfere with ion housekeeping 
in skeletal muscle cells18. Our panel of antibodies thus provides a unique 
and highly versatile tool to study the topography, structure and function 
of GAGs. Here, we describe the selection, and evaluation of single chain 
variable fragment (scFv) antibodies against specifi c GAG epitopes. 
Phage display
One of the most successful applications of phage display has been the 
selection of specifi c antibodies from phage display libraries19- 21. DNA’s 
encoding antibodies are cloned into a suitable vector as a fusion to the gene 
encoding one of the phage coat proteins (pIII, pVI, or pVIII). Upon assembly 
in bacteria, the antibody-coat protein fusion will be part of the surface of 
the phage, thus “displaying” the antibody. A phage display library is a 
large collection of phages each displaying an individual antibody. Phage 
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display allows the generation of antibodies against “self antigens” which 
is favorable since GAGs are largely non-immunogenic.
The phage display system is illustrated in Fig. 1. First, the phage display 
library is incubated with the “antigen” (GAGs) immobilized onto a tube. 
Phages that display antibodies that are specifi c for the antigen will bind, 
non-adherent phages will be washed away. Phages expressing a specifi c 
anti-GAG antibody can then be recovered from the tube (e.g. by altering the 
pH), and multiplied by infection into bacteria. This biopanning procedure 
is repeated several times. Selected phages are then analyzed for anti-GAG 
antibodies by ELISA and immunohistochemistry.
In principle, any phage display library can be used. In the protocol 
described here, a human semi-synthetic library [Library #122] was used, 
consisting of > 108 diﬀ erent clones, each expressing a unique antibody. The 
semi-synthetic Library #1 contains 50 diﬀ erent VH genes combined with a 
single light chain gene (DPL 16). In the library, variable parts of the heavy 
and light chains are joined to each other by a linker sequence to form so-
called single chain variable fragments (scFv). All antibodies contain a c-Myc 
tag for identifi cation. Due to the use of an amber codon combined with a 
suppressor Escherichia coli (E. coli) strain, one can easily produce soluble 
scFv antibodies from selected phage clones.  To rescue and amplify phages 
following selection, a helper phage is required to allow for phage assembly. 
VCS-M13 is a commonly used helper phage that bears the kanamycin-
resistance gene, which, along with the ampicillin-resistance gene carried 
by compatible phagemids, enables the selection of cells that contain 
both the helper phage and the phagemid. Helper phages usually have a 
defective origin of replication23, which allows the preferential packaging of 
the phagemid DNA over the helper phage DNA, and results in a greater 
output of phagemid phage over helper phage. This is especially important 
during selection, since only the phagemid contains the DNA encoding the 
antibody of interest.
Preparation of helper phage VCS-M13
Materials
 Bacterial strain: E. coli TG1 suppressor strain (K12, supE, hsd∆5, thi, 
∆(lac-proAB), F’(traD36, proAB+, lacIq, lac-Z∆M15))Note 1
Solutions
 Ampicillin (100 mg/ml)
 H-top agar: 10 g/l Peptone, 8 g/l NaCl, 8 g/l Bacto-Agar in H2O; dissolve, 
bring the volume to 1 l with H2O. Autoclave and store at 4°C. Melt in a 
microwave before use.
Chapter 2
34
Table 1. Characteristics of diﬀ erent scFv antibodies.
Given are the scFv antibody code, VH germ line gene family, DP gene segment number, 
amino acid sequence of the VH complementarity determining region 3 (CDR3), and the 
class of GAG with which the antibody reacts. Selection of the antibodies is described in 
the indicated reference. GAG, glycosaminoglycan; HS, heparan  sulfate; CS, chondroitin 
sulfate; DS, dermatan sulfate. All scFv antibodies recognize specifi c epitopes as based on 
diﬀ erent staining patterns and diﬀ erent reactivities toward various HS/CS/DS preparations. 
 H-bott om plates: 10 g/l Peptone, 8 g/l NaCl, 15 g/l Bacto-Agar in H2O; 
dissolve, bring the volume to 1 l with H2O and autoclave. Mix gently 
and pour into petri dishes. (Plates are stored at 4°C).
 Kanamycin (25 mg/ml)
 Minimal media agar plates: 15 g/l Bacto-agar, 10.5 g/l K2HPO4, 4.5 g/l 
KH2PO4, 1 g/l (NH4)2SO4, 0.5 g/l sodium citrate in 985 ml H2O; dissolve 
and autoclave. Cool the solution to 60°C and add 500 μl of 20% MgSO4, 
0.5 ml of 1% B1 (thiamine HCl, fi lter-sterilized 0.2 μm) and 5 ml 40% 
glucose (fi lter-sterilized 0.2 μm). Mix gently and pour into petri dishes. 
(Plates are stored at 4°C).
 0,1 M NaOH/1% (w/v) SDS
 Phosphate-buﬀ ered saline (PBS) 
 20% (w/v) polyethylene glycol 6000 (PEG)/2.5 M NaCl
 TE (Tris/EDTA) buﬀ er: 10 mM Tris HCl, pH 8.0 and 1 mM EDTA, pH 
8.0
 1 M Tris HCl, pH 7.4
 2 × TY medium
 2 × TY medium containing 100 μg/ml ampicillin and 1% glucose
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Figure 1. Schematic outline of the phage display technique. A library of phage-infected 
bacteria is grown and induced to produce phages expressing (“displaying”) scFv antibody 
fragments on their surface (A). Phages are isolated (B) and used for selection (“panning”; C) 
against glycosaminoglycans (GAGs), which are immobilized onto the surface of a selection 
tube. Non-binding phages are washed away, whereas phages displaying antibodies that 
are reactive with GAGs stay bound to the tube. Thus, the library becomes enriched for 
phages displaying GAG-reactive antibodies. Selected phages are harvested (D), allowed 
to infect a fresh E. coli culture, and used for another round of panning (A-D). Individual 
clones can be isolated after 4 rounds of panning.  Insert top left: schematic representation 
of the phagemid encoding antibody-expressing phages. At the bottom a 3D-model of a scFv 
antibody showing the light and heavy chain (ribbon) and the CDR3 region is depicted (space 
fi lling). CDR3, complementarity determining region 3.
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 TYE plates: 10 g/l Peptone, 5 g/l Bacto-Yeast extract, 8 g/l NaCl, 15 g/l 
Bacto-Agar in H2O; dissolve, bring the volume to 1 l and autoclave. Cool 
the solution to 60°C and add 1ml of 100 mg/ml ampicillin and 25 ml of 
40% glucose to achieve fi nal concentrations of 100 μg/ml ampicillin and 
1% glucose. Mix gently and pour into petri dishes. (Plates are stored at 
4°C).
Note 1 E. coli TG1 is a T-phage resistant strain that harbors a mutated tRNA gene. The 
mutated tRNA will suppress the UAG amber (stop codon). To allow expression of scFv-
pIII fusion protein on the phage tip, the amber codon will be substituted by a glutamine.
Methods
Day 1
1. Streak E. coli TG1 cells from a glycerol stock on a minimal media 
agar plate and incubate o/n at 37°C. Do not use antibiotics; E. coli 
TG1 has no antibiotic resistance genes.
Day 2
1. Inoculate 5 ml 2 × TY medium containing 1% glucose with a single 
colony of E. coli TG1 cells from the minimal media agar plate and 
incubate o/n at 37°C.
Day 3
1. Inoculate 50 ml 2 × TY medium containing 1% glucose with 500 μl 
of the o/n culture. Grow the culture, while shaking, at 37°C until an 
absorbance at 600 nm of 0.4-0.5 is reached.
2. Prepare 10-6, 10-7, and 10-8 dilutions of the commercially obtained 
VCS-M13 preparation (usually in the range of 1 × 1011 plaque-
forming units (pfu)/ml) in 2 × TY medium containing 1% glucose. 
Add 10 μl of these dilutions to 200 μl E. coli TG1 cultures (Day 3; 
step 1). 
3. Incubate for 30 min at 37°C, without shaking, to allow for infection 
of E. coli cells with helper phage.
4. Add 3 ml of liquefi ed H-top agar (not warmer than 50°C) to the 
infected culture, mix gently, and pour onto H-bott om plates that 
have been pre-warmed to 37°C. Incubate o/n at 37°C. The aim is to 
obtain a plate from which single VCS-M13 plaques can be picked 
easily (i.e. E. coli colonies that are growing slower because of 
infection with VCS-M13).
5. Determine the titer of the VCS-M13 phages from the number of 
plaques. 
6. Separately, inoculate 5 ml 2 × TY medium containing 1% glucose 
with a single colony of E. coli TG1 cells from the minimal media 
agar plate (Day 1; step 1) and grow o/n at 37°C.
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Day 4
1. Inoculate 50 ml 2 × TY medium containing 1% glucose with 500 μl 
of the o/n culture (Day 3; step 5). Grow the culture, while shaking, 
at 37°C until an absorbance at 600 nm of 0.4-0.5 is reached (When 
necessary the E. coli culture can be kept on ice before infection for 
a moment. However, do not exceed 30 min because of the loss of 
F-pili).
2. Transfer a single VCS-M13 plaque from the H-bott om plate (Day 
3; step 4) to 4 ml of the E. coli culture (step 1) and incubate, while 
shaking, for 2 h at 37°C (phage infection). 
3. Transfer the infected 4 ml culture to a 2-liter Erlenmeyer fl ask 
containing 500 ml of pre-warmed 2 × TY medium and grow the 
culture, while shaking, for 1 h at 37°C.
4. Add 1.2 ml of 25 mg/ml kanamycin to a fi nal concentration of 60 
μg/ml and grow, while shaking, o/n at 37°C.
Day 5
1. Cool the culture (Day 4; step 4) on ice for 20 min.
2. Collect the bacteria by centrifugation at 5,000g for 10 min at 4°C 
(after centrifugation phages are present in the supernatant!).
3. Add 100 ml of ice-cold PEG-NaCl to the phage supernatant, mix 
gently and incubate on ice for 1 h. In this step phages are precipitated.
4. Pellet the phages at 10,000g for 30 min at 4°C.
5. Resuspend the phage pellet in 40 ml H2O. Transfer the solution to 
a 50 ml tube and add 8 ml of ice-cold PEG-NaCl. Mix well and 
incubate on ice for 20 min.
6. Centrifuge the phage solution at 10,000g for 30 min at 4°C. Decant 
the supernatant, centrifuge briefl y and remove residual PEG-NaCl 
with a capillary. 
7. Resuspend the phage pellet in 2.5 ml of TE buﬀ er and centrifuge at 
10,000.
8. Wet a 0.45 disposable fi lter with TE buﬀ er and fi lter the phage 
solution to remove any remaining bacterial debris. Note that it can 
be diﬃ  cult to fi lter the phage solution and that this step may result 
in the loss of phages that remain in the fi lter. 
9. Titrate the phages to 10-12 pfu/ml.
10. Store the phage solution at 4°C (up to 5 days).
Panning methodology
Panning methodology (Fig. 1, Table II) involves the physical contact of 
the phage display library with the antigen (in this case GAGs), and can 
be regarded as an aﬃ  nity selection system. In practice, a small volume 
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containing the phage display library is incubated with the antigen 
immobilized to a tube. Panning consists of several rounds of binding phages 
to the immobilized GAGs, a defi ned number of washing steps, and elution 
of the bound phages by altering the pH. Eluted phages are subjected to 
another round of panning. During each round of panning specifi c binding 
clones are selected and amplifi ed so they predominate after three to four 
rounds of panning. The input of each round should be in the range of 1012 
phages.
Selection of phages displaying specifi c antibodies against GAGs using 
panning methodology
Materials
 Bacterial strain: E. coli HB2151 non-suppressor strain (K12, ara, thi, 
∆(lac-pro),  F’(proAB+, lacIq, Z∆M15)
 Bacterial strain: E. coli TG1 suppressor strain (K12, supE, hsd∆5, thi, 
∆(lac-proAB), F’(traD36, proAB+, lacIq, lac-Z∆M15))
 Glycerol stock of the (semi)-synthetic scFv Library #122 [Dr. G. Winter, 
MRC Centre for Protein Engineering, Cambridge, UK], stored at -80°C
 VCS-M13 helper phagesNote 2 used at a titer of 1 × 1012 pfu/ml (Stratagene, 
for large amounts see preparation of helper phage VCS-M13)
Note 2 VCS-M13 phages provide phage coat proteins and enzymes which are crucial for 
rescue of the phages.
Solutions
 GAGs of interest: 10 mg/ml in H2O PBS containing 0.1% (v/v) Tween-20
 PBS containing 2% (w/v) Marvel (prepare freshly)
 PBS containing 4% (w/v) Marvel (prepare freshly)
 100 mM triethlyamine (prepare freshly)
 2 × TY containing 100 μg/ml ampicillin and 25 μg/ml kanamycin
Methods
Several precautions need to be taken to avoid carry-over of phages during 
the selections. The use of sterile solutions and disposable plastics is 
highly recommended. Non-disposable plastics should be soaked for 1 h 
in 2% (v/v) hypochlorite, followed by thorough washing and autoclaving. 
Glassware should be baked for at least 6 h at 180°C. Always use aerosol-
resistant pipett e tips (Molecular Bio-Products) when working with phages. 
It is recommended to work in a laminar-fl ow cabinet. Clean the workplace 
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(bench tops, etc.) with 0.1 M NaOH/1% (w/v) sodium dodecyl sulfate (SDS) 
before and after each working day. Clean pipett es etc. daily by wiping the 
outside with 0.1 M NaOH/1% (w/v) SDS, followed by a rinse with water.
Table 2. Time schedule of experiments described in this chapter.
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For a schematic representation of the following steps see Fig. 1.
(A) Growth of antibody phage display library
1.1. Inoculate 50 ml of 2 × TY containing 100 μg/ml ampicillin and 1% 
glucose with 50 μl from a glycerol stock of the (semi)-synthetic scFv Library 
#122.
1.2. Grow the culture, while shaking, at 37°C until an optical density at 600 
nm of 0.5 is reachedNote 3. (This takes about 2-3 h).
1.3. Transfer 10 ml of the culture to a sterile 50 ml tube and add 50 μl 
VCS-M13 helper phagesNote 4. The ratio between bacteria and helper phages 
must be 1:20 (titer helper phages 1012 pfu/ml).
1.4. Incubate at 37°C for 30 min without shaking (phage infection).
1.5. Centrifuge the infected culture at 4,000g for 10 min at room temperature. 
Decant the supernatant, and resuspend the pellet in 1 ml 2 × TY containing 
100 μg/ml ampicillin and 25 μg/ml kanamycin. 
1.6. Add the infected bacterial suspension to 300 ml of pre-warmed (30°C) 2 
× TY containing 100 μg/ml ampicillin and 25 μg/ml kanamycin (no glucoseNote 
5). Incubate o/n, while shaking, at 30°C. This culture will be used in section 
B: ‘Isolation of phages; step 1.1.’.
Inoculate 10 ml of 2 × TY with a single colony of E. coli TG1 from a minimal 
medium plate (do not use antibiotics) and grow o/n, while shaking, at 
37°C. This culture will be used in section C: ‘Selection of phages binding to 
GAGs; Day 2, step 2.8.’.
Note 3 M13 phages infect F+ E. coli via sex pili. For optimal infection, E. coli needs to be in 
the log phase (absorbance of 0.4-0.5 at 600 nm) at 37°C. When grown to a higher density, 
sex pili are lost very rapidly. A log phase culture can be held on ice for about 30 min. 
Note 4 Take the remaining 40 ml of the culture, spin it down, and resuspend the pellet in 
1 ml 2 × TY. Spread it on TYE plates, and grow overnight at 37°C. Harvest the cells in 
2 × 5 ml 2 × TY medium. Collect the cells in a 50 ml tube and centrifuge for 10 min at 
10,000g. Resuspend the pellet in 500 μl of 2 × TY, add 500 μl of 60% glycerol to a fi nal 
concentration of 30%, mix well, divide this stock in 50 μl aliquots, and store at -80°C as a 
back up for additional selections (this stock will be the n+1 generation).
Note 5 Glucose represses transcription of the scFv-pIII fusion protein through the Lac operon 
in the phagemid.
(B) Isolation of phages
1.1. Cool the culture A: ‘Growth of antibody phage display library; step 
1.6.’ on ice for 10 min. 
1.2. Centrifuge the culture at 5,000g for 15 min at 4°C. After centrifugation, 
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the bacterial pellet can be discarded and the supernatant containing the 
phages is transferred into a sterile bucket. 
1.3. Add 60 ml of ice-cold PEG-NaCl to the supernatant to precipitate the 
phagesNote 6. Mix well by inverting, and leave the bucket on ice for 1 h. 
1.4. Pellet the phages at 10,000g for 30 min at 4°C. Resuspend the pellet in 
40 ml of ice-cold, sterile H2O. Transfer the phage suspension to a 50 ml tube 
and add 8 ml of ice-cold PEG-NaCl. Mix well (as in step 1.3.) and leave on 
ice for 20 min.
1.5. Centrifuge the phage mixture at 10,000g for 30 min at 4°C. Decant 
the supernatant, centrifuge briefl y and remove residual PEG-NaCl with a 
capillary.
1.6. Resuspend the phage pellet in 2.5 ml PBS and centrifuge the phage 
solution at 10,000g for 5 min.
1.7. Wet a 0.45 μm disposable fi lter with PBS and carefully fi lter the phage 
solution to remove any remaining bacterial debris. Note that it can be 
diﬃ  cult to fi lter the phage solution. 1.8. This step may result in loss of 
phages that remain in the fi lter. 
1.9. Store the phage solution at 4°C until use. Phages will be used in section 
C: ‘Selection of phages binding to GAGs; Day 2, step 2.2.’.
Note 6 In this step phages are precipitated and concentrated. Given that the TG1 suppression 
of the amber codon is never complete, this step is also necessary for removing any soluble 
antibodies present in the supernatant.
(C) Selection of phages binding to GAGs
Day 1
1.1. Coat immunotubes with 3 ml of a 10 μg/ml solution of the GAG of 
interest and incubate o/n at room temperature, while rotating on an under-
and-over turntable. 
Day 2
2.1. Decant the GAG solution, wash the tube 3 times with PBS and block the 
tube with PBS containing 2% (w/v) Marvel to avoid non-specifi c binding 
of phages to the surface of the tube. Fill the tube to the edge, cover it with 
Parafi lm, and incubate for at least 2 h at room temperature on an under-
and-over turntable. This step should be performed early in the day, so that 
the tube will be ready when the phages used for biopanning are obtained 
B: ‘Isolation of phages; step 1.8.’.
2.2. Empty the tube and add 2 ml of PBS containing 4% Marvel and 2 ml of 
phage supernatant from B: ‘Isolation of phages; step 1.8.’, cover the tube, 
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and incubate for 1 h on an under-and-over turntable at room temperature, 
followed by standing for 1 h.
2.3. Discard the phage suspension and wash the tube 20 times with PBS 
containing 0.1% (v/v) Tween-20. After the last wash, fi ll the tube with PBS 
containing 0.1% (v/v) Tween-20 and rotate on an over-and-under turntable 
for 10 min at room temperature.
2.4. Empty the tube and wash the tube 20 times with PBS. Fill the tube with 
PBS and rotate on an over-and-under-table for 10 min at room temperature.
2.5. Empty the tube and add 1 ml of 100 mM triethlyamine solution. Cover 
the tube and rotate for 15 min on an under-and-over turntable at room 
temperature. In this step bound phages are eluted.
2.6. Add the eluted phages to a 50 ml tube containing 0.5 ml of 1 M Tris-HCl, 
pH 7.4 for neutralization. Additionally, add 200 μl of 1 M Tris-HCl, pH 7.4 
to the remaining phages in the immunotube. At this point phages can be 
stored at 4°C for a short period of time (up to 2 days), or used directly to 
infect E. coli TG1 cells. The latt er is recommended. 
2.7. Add the eluted phages (step 6) to 9 ml of exponentially growing E. coli 
TG1 cells in a 50 ml tube. Add 4 ml TG1 culture to the remaining phages 
in the immunotube (step 6). Incubate both cultures for 30 min at 37°C, 
without shaking, to allow infection. 
2.8. Exponentionally growing TG1 culture is prepared as follows: Inoculate 
50 ml of 2 × TY with 0.5 ml of the o/n culture from section A: ‘Growth of 
antibody phage display library; step 1.7.’. Grow the culture, while shaking, 
at 37°C until an absorbance at 600 nm of 0.4-0.5 is reached (this takes about 
90 min). It is recommended to inoculate an additional 50 ml of 2 × TY with 
0.5 ml of the overnight culture 30 and 60 min after the fi rst inoculation and 
use the culture with an absorbance of 0.4-0.5 for infection.
2.9. Pool both infected E. coli TG1 cultures (9 ml and 4 ml from step 2.8.) 
and take 100 μl of the pooled cultures to make serial dilutions (102, 104, 
106, 108) in 2 × TY to calculate the titer. Plate 100 μl of the dilutions on TYE 
plates and grow o/n at 37°C. 
2.10. Centrifuge the infected TG1 culture for 10 min at 10,000g at room 
temperature (do not refrigerate!). 
2.11. Resuspend the cells in 2 ml 2 × TY, spread on TYE plates and incubate 
o/n at 37°C.
Day 3
3.1. Count colonies and calculate the titer from the dilutions. An increase 
in titer is expected after each selection round, indicating enrichment of 
binding clones. Store plates with separate colonies, since individual clones 
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will be used in section E: ‘Production of master plate and induction plate 
of phage infected clones; Day 3, step 3.1.’.
(D) Harvesting of selected phagemids
3.2. Add 5 ml 2 × TY medium to the TYE plates and scrape the bacterial 
cells from the plate with a glass spreader. Collect the bacteria in a 50 ml 
tube and centrifuge at 5,000g for 10 min at room temperature. 
3.3. Decant the supernatant and resuspend the bacterial pellet in 2 ml 2 × 
TY medium.
3.4. For a next round of selection, take 50 μl of the bacterial suspension 
and use it to inoculate 50 ml 2 × TY containing 100 μg/ml ampicillin and 
1% (w/v) glucose as in A: ‘Growth of antibody phage display library; step 
1.1.’. Repeat this selection procedure for another 3 selection rounds (all 
steps of this section).
3.5. Add 1 ml of ice-cold 60% glycerol to the remaining cells, aliquot in 50 
μl fractions, snap freeze in liquid nitrogen, and store at -80°CNote 7.
Note 7Glycerol stocks are used as a backup. When a subsequent selection round fails, use the 
glycerol stock for a new round of selection. 
Screening for clones expressing anti-GAG antibodies 
To assess whether or not the panning experiment was successful, individual 
clones need to be selected and analyzed. This section describes a procedure 
to identify antibody-expressing clones after panning. An easy and fast 
method to test the selected clones for production of antibodies directed 
against GAGs is enzyme-linked immunosorbent assay (ELISA). Antibody-
containing supernatants obtained from isopropyl-β-D-thiogalactosidase 
(IPTG)-induced cultures can be used for this purpose. Clones with desired 
specifi city in ELISA can be further analyzed by DNA sequencing to identify 
diﬀ erent clones e.g. with unique CDR3 sequences. Clones of interest can 
then be used for large scale production and purifi cation.
(E) Production of master plate and induction plate of phage infected clones
Materials
 Sterile 96-well fl at-bott om assay plates with high-binding surface 
(ELISA plate, Greiner) 
 96-wells round-bott om Cellstar plates (master block) (Greiner) 
 p-Nitrophenyl phosphate disodium salt, hexahydrate (PNPP, MP 
Biomedicals)
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Solutions
 1 M diethanolamine, pH 9.8. Store in the dark at room temperature.
 GAGs of interest 10 mg/ml in H2O 1 mM IPTG in H2O (prepare freshly) 10 mM IPTG in 2 × TY
 PBST: 0.05 ml/l Tween-20 in PBS
 Secondary antibody solution: Mouse anti-c-Myc antibody (9E10, 
hybridoma culture supernatant Note 8) diluted 1:10 with PBST containing 
2% (w/v) bovine serum albumin (BSA)
 Tertiary antibody solution: Alkaline phosphatase-conjugated rabbit 
anti-mouse IgG (DAKO) diluted 1:2,000 with PBST containing 2% 
(w/v) BSA 
 Substrate solution: Add 1 mg PNPP/ml to 1 M diethanolamine solution 
(prepare freshly). 
 Washing solution: PBS containing 0.1% (v/v) Tween-20
Note 8 The Hybridoma cell line (9E10 (anti-c-Myc)) is available from the American Type 
Culture Collection (ATCC). Alternatively, polyclonal rabbit anti-c-Myc antibody (A14, 
Santa Cruz Biotechnology) or purifi ed 9E10 (Sigma) can be used.
Methods
Day 3
3.1. Pick individual bacterial clones with sterile tooth picks from the serial 
dilution plates of the last two selection rounds (round 3 and 4) (C: ‘Selection 
of phages binding to GAGs; Day 3, step 3.1.’), and inoculate individual wells 
of a 96-well master block, fi lled with 500 μl of 2 × TY containing 100 μg/ml 
ampicillin and 1% glucose. Repeat this for 94 individual clones. Include a 
negative control (medium without bacterial clones) and a positive control 
(a clone that reacts with the antigen). When no positive clone is available, 
leave the well empty and use a commercially available antibody for further 
analysis. Secure the lid with tape and grow o/n, while shaking, at 37°C. 
Day 4
4.1. Transfer 10 μl bacterial culture (Day 1, step 1) to the corresponding 
wells of a secondary sterile master block containing 1 ml 2 × TY containing 
100 μg/ml ampicillin and 0.1% glucoseNote 9. This plate will be the induction 
plate. Secure the lid with tape, and grow at 37°C, while shaking, for 3 h Note 
10. Do not exceed 200 rpm to prevent contamination.
4.2. When bacterial growth is clearly visible in the induction plate an 
absorbance at 600 nm of ~0.9 is reached. For induction, add 100 μl of 10 
mM IPTG in 2 × TY to each well of the induction plate to reach a fi nal 
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concentration of 1 mM IPTG. Incubate the plate, while gently shaking (do 
not exceed 200 rpm to prevent contamination) o/n at 30°C to induce the 
production of anti-GAG antibodies. 
4.3. Fill a master block with 200 μl of the o/n culture and add 200 μl of 
ice-cold 60% glycerol to all wells to a fi nal concentration of 30% (use a 
multichannel pipett or). Mix well, and store the plate immediately at -80°C. 
This plate will be the master plate and is used as a back up.
Note 9 Glucose (0.1%) is added to suppress the expression of scFv antibodies until a suﬃ  cient 
number of bacteria is produced for large scale production of the antibody. The total amount 
of glucose will be fully metabolized at an absorbance of 0.9 at 600 nm.
Note 10 Grow the culture in the induction plate for 3 h at 37°C while shaking. Bacterial 
growth should be clearly visible before adding IPTG.
Day 5
5.1. Centrifuge the induction plate (Day 2; step 2) for 30 min at 5,000g 
to pellet bacteria. The supernatant containing antibodies will be used to 
screen for positive clones as described in the following section.
(F) ELISA screening for bacterial clones expressing anti-GAG antibodies
Methods
Day 4
4.1. Coat wells from an ELISA plate with 100 μl of a 10 μg/ml GAG solution. 
Incubate o/n at 4°C. This step can be performed at day 2 of the previous 
section.
Day 5
5.1. Discard the GAG solution and wash the plate 6 times with PBST.
5.2. Block the plate with 200 μl of 2% (w/v) BSA in PBST for 90 min at room 
temperature. 5.3. Empty the plate and add 100 μl culture supernatant from 
the induction plate (E: Production of master plate and induction plate 
of phage-infected clones; Day 5, step 5.1.) containing soluble antibodies 
to the corresponding wells of the ELISA plate. Incubate for 2 h at room 
temperature Note 11.
5.4. Discard the culture supernatant and wash the plate 6 times with PBST.
5.5. Add 100 μl of the secondary antibody solution to each well and incubate 
for 1 h at room temperature.
5.6. Discard the secondary antibody solution and wash the plate 6 times 
with PBST.
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5.7. Add 100 μl of the tertiary antibody solution to each well and incubate 
for 1 h at room temperature.
5.8. Discard the tertiary antibody solution and wash the plate 6 times 
with PBST. This step is followed by a single wash with 100 μl of 1 M 
diethanolamine solution to reduce background signals.
5.9. Add 100 μl of substrate solution to each well and incubate in the dark 
at room temperature until color development is clearly visible. 
5.10. Read the absorbance on an ELISA reader at 405 nm.
Note 11 Include negative controls (i.e. supernatant without scFv antibodies) and positive 
controls (if available).
(G) Large scale production of periplasmic fractions containing soluble scFv 
antibodies 
To obtain large amounts of soluble antibodies, periplasmic fractions of 
bacteria expressing the antibodies are used. Upon induction with IPTG, scFv 
chains are expressed with the N-terminal pelB bacterial leader sequence that 
targets the chains to the periplasm, where the pelB sequence is cleaved oﬀ  by 
the enzyme signal peptidase. Within the periplasm, appropriate oxidizing 
conditions allow the antibody to fold, and form functional scFv antibodies. 
Soluble scFv antibodies are obtained from the bacterial periplasm, through 
the addition of borate buﬀ er, which selectivity releases periplasmic 
proteins. Antibodies contained in this crude periplasmic fraction can be 
purifi ed by various ways, e.g. by metal chelate chromatography using a 
His tag. However, the pHEN-1 vector into which the library is cloned (Fig 
2.) yields scFv antibodies with a c-Myc tag. To circumvent high background 
signals in immunohistochemistry on e.g. tumor tissue (which express 
c-Myc), scFv antibodies are subcloned into pUC119-His-VSV (Fig. 2; Raats, 
Department of Biochemistry (NWI), Nijmegen Centre for Molecular Life 
Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands). 
This vector contains both a His- and VSV tag for purifi cation and detection. 
Both the pHEN and the pUC119 vector contain β-lactamase (ampicillin 
selection) and a LacZ promoter upstream of the antibody gene of interest 
(IPTG induction of antibody expression). 
Materials
 EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics)
 Glycerol stock of bacteria producing anti-GAG antibody, stored at 
-80°C
 Dialysis membrane (Medicell International, molecular weight cut-oﬀ  < 
20 kDa)
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Figure 2.
(A) Schematic representation of 
plasmid pUC119-HV, harbouring 
the DNA encoding scFv antibody 
HS4C3 (pUC119-HV-HS4C3). (B) 
HS4C3-coding sequence cloned 
into plasmid pUC119-HV (NcoI-
NotI cloning). Depicted are: Amp, 
ampicillin resistance-encoding 
gene; P LacZ, LacZ promoter; pelB, 
signal peptide of bacterial pectate 
lyase that targets antibodies to 
the periplasmic space; (G4S)3-
linker, a 15 amino acid linker 
sequence connecting the VH 
and VL domains; His-tag, eight 
histidine residues used for protein 
purifi cation; VSV-tag, peptide 
epitope used for immuno-detection. 
Sequences encoding VH and VL 
complementarity determining 
regions (CDRs) are shaded. Also 
indicated are the nucleotide 
sequences of PCR primers that can 
be used for sequencing (pUC/M13-s 
and PelBseq-s).
Solutions
 Ampicillin (100 mg/ml)
 0.5 M Boric acid
 Borate buﬀ er: adjust 0.5 M boric acid to pH 8.0 with 0.5 M sodium 
borate. Store at room temperature. Prior to use, add 1 EDTA-free 
protease inhibitor tablet, and 1.6 ml of 5 M NaCl to 16 ml of the borate 
buﬀ er, and adjust the volume to 40 ml with H2O
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 LB medium
 LB medium containing 1% glucose and 100 μg/ml ampicillin
 0.5 M Sodium borate
 TYE plates
 2 × TY containing 100 μg/ml ampicillin and 0.1% glucose
 2 × TY containing 100 μg/ml ampicillin and 1% glucose
Methods
Day 6
6.1. Streak individual clones that express GAG binding antibodies from a 
master plate on TYE plates and incubate o/n at 37°C.
Day 7
7.1. Inoculate 20 ml 2 × TY containing 100 μg/ml ampicillin and 1% (w/v) 
glucose with a single colony from a fresh streak of an antibody-expressing 
clone. Incubate o/n, while shaking, at 37°C. Plates can be stored at 4°C for 
up to 1 month.
Day 8
8.1. Inoculate 1 l of 2 × TY containing 100 μg/ml ampicillin and 0.1% (w/v) 
glucose with 10 ml of the o/n culture bacterial culture and incubate, while 
shaking, at 37°C until an absorbance at 600 nm of 0.5-0.8 is reached. This 
takes about 2.5 to 3 h. 
8.2. As a back up for additional antibody production a glycerol stock is 
prepared. Add 500 μl of 60% glycerol to 500 μl of the o/n culture. Mix 
well, freeze in liquid nitrogen and store at -80ºC. 1.5 ml of the remaining 
o/n culture is used for DNA miniprep and sequencing as described in the 
section ‘Sequence analysis of selected clones’.
8.3 To the 1 l of induction culture add 1 ml of 1 M IPTG to a fi nal concentration 
of 1 mM IPTG and incubate the culture, while shaking, for 3 h at 30°C.
8.4. Cool the culture on ice for 20 min.
8.5. Collect the bacteria by centrifugation at 5,000g for 10 min at 4°C. Decant 
the supernatant, and add 10 ml of ice-cold borate buﬀ er to the bacterial 
pellet. Borate buﬀ er dissolves the glycocalix. scFv antibodies which are 
present in the periplasmic space become available and can be readily 
isolated.
8.6. Resuspend the pellet by vortexing and pipett ing vigorously. Transfer 
the mixture to a 50 ml tube and centrifuge at 10,000g for 30 min at 4°C. 
The supernatant is the periplasmic fraction containing the soluble scFv 
antibodies.
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8.7. Filter the periplasmic fraction through a 0.45 μm disposable fi lter.
8.8. Dialyze the periplasmic fraction o/n against PBS at 4°C.
Day 9
9.1. Divide the periplasmic fraction in aliquots (1 ml). Store at 4°C for direct 
use or freeze and store at -20°C to -80°CNote12.
Note 12 The stability of scFv antibodies is highly variable. Whereas some antibodies can be 
stored at 4°C for weeks to months, others stay immunoreactive for only a couple of days. 
Most antibodies can be stored at -80°C for years. Bacterial supernatants containing scFv 
antibodies can be used for ELISA, but are often not suitable for immunohistochemistry. 
Periplasmic fractions, containing scFv antibodies which are more concentrated, are suitable 
for both. For immunoprecipitation or addition to cell cultures, antibodies may be purifi ed 
using Protein A (in case of antibodies belonging to the VH3 family)  or metal chelating 
column chromatography.
 
(H) Sequence analysis of selected clones
For DNA sequence analysis, purifi ed phagemid DNA from an o/n culture 
of the selected clones is used, which can easily be isolated by a commercially 
available small-scale plasmid preparation kit. Sequence analysis of the 
antibody-producing clones is performed with one of the oligonucleotide 
primers given below or any other suitable primer. The sequence can then 
be analyzed using the alignment program IgBLAST, which can be found on 
the internet at htt p://www.ncbi.nlm.nih.gov/igblast/. VH CDR3 sequences 
are especially useful to identify individual clones. 
Materials
 Plasmid DNA isolation kit (e.g., QIAprep Spin Miniprep Kit, QIAGEN)
 Sequencing kit (e.g., ABI Prism)
 Sequencing primers (see Fig. 2 for details and location on vector)
o Forlinkseq: 5’ –GCC ACC TCC GCC TGA ACC– 3’ (sense)
o PelBseq: 5’ –CCG CTG GAT TGT TAT TAC TC– 3’ (anti-sense)
 
Solution
 o/n culture of a selected bacterial clone grown at 37 ºC.
Methods
8.1 Take 1.5 ml of the o/n culture (Large scale production of periplasmic 
fractions containing soluble scFv antibodies; Day 8, step 8.1.) and 
centrifuge 5 min at 5,000g.
8.2. Decant the supernatant and use the bacterial pellet for isolation of 
plasmid DNA according to the manufacturers’ protocol. 
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8.3. Mix suitable amounts of miniprep DNA and sequencing primer and 
submit for sequencing according to the manufacturers’ protocol.
We have generated a large number of unique scFv antibodies which are 
specifi c for unique epitopes on GAG chains. Table 1 shows a selection of 
the scFv antibodies obtained. Note that all antibodies are diﬀ erent with 
respect to their CDR3.
(I) Evaluation of specifi city of anti-GAG antibodies by immunofl uorescence
To investigate GAG specifi city of the scFv antibodies, cryosections can be 
incubated overnight with the glycosidases heparinase I (0.04 IU/ml in 50 
mM NaAc/50 mM Ca(Ac)2, pH 7.0 at 37°C) (E.C. 4.2.2.7)Note13, heparinase 
II (0.04 IU/ml in 50 mM NaPO4, pH 7.1 at 37°C), heparinase III (0.04 IU/
ml in 50 mM NaAc/50 mM Ca(Ac)2, pH 7.0 at 37°C) (E.C. 4.2.2.8), or a mix 
of these enzymes, to digest HS/heparin. CS and DS can be digested from 
cryosections by o/n incubation with the chondroitin lyases chondroitinase 
AC which digests CS (1 IU/ml in 25 mM Tris-HCl, pH 7.5 at 37°C), 
chondroitinase ABC which digests both CS and DS (1 IU/ml in 25 mM Tris-
HCl, pH 8.0 at 37°C), or chondroitinase B which digests DS (1 IU/ml in 
25 mM Tris-HCl, pH 7.5 at 37°C). As a control, digestion buﬀ er without 
the enzyme can be used. Digested cryosections are incubated with mouse 
anti-HS stub IgG antibody 3G10 to check for heparinase pretreatment or 
with mouse anti-CS/DS stub IgG antibody 2B6 to check for chondroitinase 
pretreatment. 
Note 13 E.C. is the Enzyme Commission number.
Materials 
 Coverslips
 2-5 μm tissue cryosections on glass slides
Solutions
 Chondroitinase ABC, AC, B (Seikagaku)
 Heparinase I, II, III (IBEX)
 GAG digestion buﬀ ers:
o Heparinase I, III, digestion buﬀ er: 50mM NaAc and 50 mM, 
Ca(Ac)2, pH 7.0
o Heparinase II digestion buﬀ er: 50 mM NaPO4, pH 7.1
o Chondroitinase AC, B digestion buﬀ er: 25 mM Tris-HCl, pH 7.5
o Chondroitinase ABC digestion buﬀ er: 25 mM Tris-HCl, pH 8.0
 Mouse anti-HS stub IgG antibody 3G10 (Seikagaku)
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 Mouse anti-CS/DS stub IgG antibody 2B6 (Seikagaku)
 Mowiol solution (Calbiochem): (10% (w/v) in 0.1 M Tris-HCl, pH 
8.5/25% (v/v) glycerol/2.5% (w/v) NaN3)  Primary antibody solution: periplasmic fraction diluted in PBST 
containing 2% (w/v) BSA, such that the antibody gives maximal specifi c 
fl uorescence and minimal background staining.
 Secondary antibody solution: Mouse anti-c-Myc antibody (9E10, 
hybridoma culture supernatant9) or mouse anti-VSV antibody (P5D4, 
hybridoma culture supernatantNote 14) diluted 1:10 with 2% (w/v) BSA 
in PBST.
 Tertiary antibody solution: (Alexa-488)-conjugated anti-mouse IgG 
antibody (Molecular Probes) diluted 1:250 with 2% (w/v) BSA in PBST.
Note 14 The Hybridoma cell line (P5D4 (anti-VSV)) is available from the American Type 
Culture Collection (ATCC). Alternatively, polyclonal rabbit anti-VSV-G (Sigma) can be 
used.
Methods
1. Air-dry the cryosections for 30 min prior to use, to ensure att achment 
to microslide surface and to preserve the structure.
2. Re-hydrate the cryosections with PBS for 5 min.
3. Block free binding sites with 2% (w/v) BSA in PBST for 20 min.
4. Incubate cryosections with the primary antibody solution for 45 
min.
5. Remove the primary antibody solution and wash 3 times 5 min 
with PBST.
6. Incubate cryosections with secondary antibody solution for 30 min.
7. Remove secondary antibody solution and wash 3 times 5 min with 
PBST.
8. Incubate cryosections with tertiary antibody solution for 30 min.
9. Remove tertiary antibody solution and was 3 times 5 min with 
PBST.
10. Fix cryosections in 96% ethanol for 10 seconds.
11. Air-dry the sections and use mowiol solution for embedding; store 
at -20°C.
12. Analyze staining patt erns by fl uorescence microscopyNote 15. 
Fig. 3 is an example of staining patt ern on renal cryosections using 
scFv antibodies.
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To evaluate the specifi city of the antibodies, cryosections can be pre-
incubated with the glycosidases in the desired buﬀ er for 2 h at the optimal 
temperature (see above).
Cryosections are washed with PBST and blocked with 2% (w/v) BSA in 
PBST as in step 4. Proceed with the above procedure (begin at step 5). For 
staining patt erns, see Fig. 4.
Note 15Stained tissue sections can be kept up for 3 years at 4°C. The fl uorescent tag (Alexa 
488) is very stable, and fading of the signal hardly occurs. Store stained sections at -20°C. 
Background staining can often be eliminated by additional blocking steps with BSA or 
with 1-5% (v/v) serum from the same species in which the tertiary antibody is raised.
Figure 3. Immunostaining of normal rat kidney cryosections with six diﬀ erent scFv 
antibodies. Cryosections were incubated with anti-heparan sulfate (HS) antibodies 
RB4EA12 (A), HS4C3 (B), AO4B08 (C), anti-chondroitin sulfate (CS) antibody IO3H10 (D), 
anti-dermatan sulfate (DS) antibody LKN1 (E), and negative control antibody MPB49 (F). G, 
glomerulus. Note diﬀ erential staining patterns. Bar = 50 μm.
(J) Characterization of scFv antibodies by ELISA
To analyze which chemical groups in heparan sulfate/heparin or 
chondroitin sulfate/dermatan sulfate are involved in antibody recognition, 
reactivity with a number of test molecules can be evaluated by additional 
ELISA experiments: (1) direct ELISA in which wells of microtiter plates are 
coated with the test molecules, or by (2) competition ELISA in which the 
scFv antibodies and test molecules are simultaneously incubated in wells 
of a microtiter plate coated with the molecule of interest. 
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(J1) Direct ELISA
Materials
See section: F: ELISA screening of bacterial clones expressing anti-GAG 
antibodies.
Figure 4. Specifi city of anti-glycosaminoglycan antibodies. Normal rat kidney 
cryosections were treated with heparinase III, chondroitinase B, or chondroitinase ABC. 
Next, cryosections were stained using anti-heparan sulfate (HS) antibody HS4C3, anti-
chondroitin sulfate (CS) antibody IO3H10, or anti-dermatan sulfate (DS) antibody LKN1. 
Bar = 50 μm.
Methods
Day 1
1. Coat wells from an ELISA plate with 100 μl of a 10 μg/ml GAG 
solution. Incubate o/n at 4°C. 
Day 2
1. Discard the GAG solution and wash the plate 6 times with PBST.
2. Block the plate with 200 μl of 2% (w/v) BSA in PBST for 90 min at 
room temperature. 
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3. Empty the plate and add 100 μl of primary antibody solution 
(periplasmic fraction diluted 1:5 with 2% (w/v) BSA in PBST) to the 
plate. Incubate for 2 h at room temperature. 
4. Proceed as under F: ELISA screening for bacterial clones expressing 
anti-GAG antibodies; Day 5 step 5.4.
5. Analyze the absorbance values to determine apparent aﬃ  nities/ 
specifi city towards various GAGs.
(J2) Competition ELISA
Materials
See section: F: ELISA screening for bacterial clones expressing anti-GAG 
antibodies.
Methods
Day 1
1. Coat wells from an ELISA plate with 100 μl of a 10 μg/ml GAG 
solution. Incubate o/n at 4°C. 
Day 2
1. Discard the GAG solution and wash the plate 6 times with PBST.
2. Block the plate with 200 μl of 2% (w/v) BSA in PBST for 90 min at 
room temperature. 
3. Discard the 2% (w/v) BSA in PBST and add 100 μl of primary 
antibody solution (periplasmic fraction diluted 1:5 with 2% (w/v) 
BSA in PBST) together with the test molecules (serially diluted) to 
the plate. Incubate for 2 h at room temperature. 
4. Proceed as under ELISA screening for bacterial clones expressing 
anti-GAG antibodies; Day 2, step 4.
5. Analyze the absorbance values to determine apparent aﬃ  nities/ 
specifi city towards various GAGs.
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Abstract 
Glycosaminoglycans (GAGs) play an important role in renal homeostasis. 
They are strongly negatively charged polysaccharides that bind and 
modulate a myriad of proteins including growth factors, cytokines and 
enzymes. With the aid of specifi c phage display-derived antibodies, the 
distribution of heparan sulfate (HS) and chondroitin sulfate (CS) domains 
in the normal human kidney was studied. HS domains were specifi cally 
located in basement membranes and/or surfaces of renal cells and displayed 
a characteristic distribution over the nephron. A characteristic location in 
specifi c parts of the tubular system was also observed. CS showed mainly 
an interstitial location. Immunoelectron-microscopy indicated specifi c 
ultrastructural location of domains. Only partial overlap with any of 7 
diﬀ erent proteoglycan core proteins was observed. 
Two HS domains, one highly sulfated (defi ned by antibody HS4C3), and 
one low sulfated (defi ned by antibody RB4Ea12), were studied for their 
cell biological relevance with respect to the proliferative eﬀ ect of FGF-
2 on human mesangial cells in vitro. FGF-2 binding was HS dependent. 
Addition of purifi ed HS4C3 antibody, but not of the RB4Ea12 antibody, 
counteracted the binding and the proliferative eﬀ ect of FGF-2, indicating 
that the HS4C3 domain is involved in FGF-2 handling by mesangial cells.
In conclusion, specifi c GAG domains are diﬀ erentially distributed in 
the normal human kidney and are likely involved in binding of eﬀ ector 
molecules like FGF-2. The availability of tools to identify and study 
relevant GAG structures allows the development of glycomimetica to 
halt for instance mesangial proliferation and matrix production as seen in 
diabetic nephropathy. 
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Introduction
Glycosaminoglycans (GAGs) are polysaccharides produced in virtually 
every cell of the human body and are secreted into the extracellular 
matrix, or retained at the cell surface. The GAG precursor polysaccharide 
undergoes a series of modifi cation reactions resulting in very complex 
structures. GAG chains are generally att ached to core proteins, forming 
proteoglycans1. Major GAG classes include heparan sulfates/heparin 
(HS/hep), dermatan sulfates (DS) and chondroitin sulfates (CS). GAGs 
are involved in a myriad of processes like growth factor binding, signal 
transduction, and cell adhesion2-4.
The importance of GAGs in the kidney has been demonstrated, among 
others, by knockout studies. Mice defi cient for the enzyme that catalyzes 
the 2-O-sulfation of HS (2-O-sulfotransferase) demonstrate agenesis of 
kidneys5. The same holds for mice lacking the enzyme glucuronyl C5-
epimerase, which catalyzes the change of glucuronic acid to iduronic acid 
residues6.
A mutation in the gene encoding glypican-3 (a membrane-bound HSPG) 
manifests itself by cystic and dysplastic kidneys in men (Simpson-Golabi-
Behmel syndrome), as well as in mice7. Alterations in GAG composition 
and/or content have been observed in a large number of renal pathologies, 
including diabetic nephropathy, glomerulonephritides, nephroblastoma 
(Wilms’ tumor), amyloidosis, polycystic kidney disease, minimal change 
nephropathy and Denys-Drash syndrome8-13. The involvement of GAGs, 
especially HS, in such a diverse group of pathologies suggests the presence 
of a large number of structurally diﬀ erent GAGs in the kidney.
The biosynthesis of GAGs allows for a large number of diﬀ erent GAG 
chains as well as for extensive structural heterogeneity within one chain. For 
example, HS consists of repeating disaccharide units containing a uronic 
acid (UA), which can be either D-glucuronic acid (GlcA) or L-iduronic 
acid (IdoA), with or without 2-O- sulfation, and a glucosamine residue, 
which can be N-acetylated (NAc), N-sulfated (NS), or N-unsubstituted. 
In addition, the glucosamine residue can be 3-, and/or 6-O- sulfated. 
A number of diﬀ erent HS disaccharides have been found in the kidney 
including GlcA-GlcNR (R can be an acetyl or a sulfate group), IdoA-
GlcNR, GlcA2S-GlcNR, IdoA2S-GlcNR, GlcA-GlcNR6S, IdoA-GlcNR6S 
and IdoA2S-GlcNR6S14-16. Furthermore, N-unsubstituted glucosamine 
(GlcNH2) residues are also found in the kidney, and account for about 
2% of the total disaccharide units present17. With combinations of these 
disaccharides, and with the knowledge that a HS chain consists of 40-160 
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disaccharides, there can be a vast number of diﬀ erent HS chains, each with 
unique disaccharide sequences. 
Studies of alterations in GAGs associated with renal pathology have 
generally been limited to the analysis of total GAG content or their major 
classes. Studies of the topology and domain structure of GAGs have been 
hampered by a lack of appropriate tools allowing detection of the diﬀ erent 
GAG domains. Only a few antibodies against these GAG domains are 
available, for instance the JM403 antibody18. We recently obtained specifi c 
tools to analyze GAG heterogeneity by selecting a large number of phage 
display-derived antibodies reactive with renal GAGs19-21. 
In this study we used a panel of these specifi c antibodies selected against 
HS, and one against CS, to establish the topography of GAG domains in 
human kidney. Furthermore, the signifi cance of two HS domains in growth 
factor handling by human mesangial cells (HMCs) in vitro was studied. 
Materials and methods 
Antibodies
Phage-display derived anti-HS antibodies
The antibodies used in this study (further referred to as scFv antibodies) 
were obtained using the phage-display technique and some of their 
characteristics are shown in Table 1. 
Table 1. Characteristics of the diﬀ erent GAG domain specifi c scFv antibodies
Given are the scFv antibody code, DP gene number, VH germ line gene family, amino acid 
sequence of the VH complementarity determining region 3 (CDR3), the class of GAG with 
which the antibody reacts, and the preferred chemical group. HS: heparan sulfate; CS: 
chondroitin sulfate. * All scFv antibodies recognize diﬀ erent epitopes as based on diﬀ erent 
staining patterns, and diﬀ erent reactivity towards various HS/CS preparations19-21, 45; unpublished 
data.
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 Antibodies specifi c for renal tubules
To study the distribution of GAG domains and core proteins over the 
nephron, the following renal tubules-specifi c antibodies (see Table 2) were 
applied: aquaporin 1, 2 and 3, RCK-105 (keratin 7), Tamm Horsfall and 
Calbindin D28k. 
Table 2. Overview of antibodies specifi c for renal tubules used in this study
Human kidney specimens
Adult human kidneys (n = 9; 1 female, 8 male; average age: 50.7 ± 5.0 years; 
range: 40–56 years) were obtained after surgical removal for renal cell 
carcinoma. Whole kidneys were excised and normal tissue was selected 
after macro- and microscopic evaluation. Patients did not have any other 
kidney disease.
Imm unohistochemical localization of GAG domains
Cry osections (5 μm) were cut, air dried, blocked for 10 min with phosphate-
buﬀ ered saline (PBS) containing 2% (w/v) bovine serum albumin, and 
incubated with primary antibody for 90 min at 22˚C. ScFv antibodies were 
detected by incubation with rabbit anti-VSV antibodies (MBL, Nagoya, 
Japan), or mouse anti-VSV antibodies (P5D4, culture supernatant), 
followed by Alexa 488- or Alexa 594-conjugated goat anti-rabbit or goat 
anti-mouse IgG (Molecular Probes, Leiden, The Netherlands) (1:100 in PBS 
containing 2% bovine serum albumin), all for 60 min at 22˚C. Antibodies 
against distinct segments of the renal tubular system were visualized using 
Alexa 488- or Alexa 594-conjugated goat anti-mouse or goat anti-rabbit IgG 
antibodies (1:100 in PBS containing 2% bovine serum albumin), for 60 min 
at 22˚C. After each incubation, sections were washed in PBS (three times 5 
min). As a control, the irrelevant scFv antibody MPB59 was used. This scFv 
antibody does not stain human kidney tissue. Additional controls were 
the omission of primary, secondary or conjugated antibody. After the last 
washing step, cryosections were fi xed in 100% ethanol for 20 seconds, air-
dried and embedded in Mowiol. 
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Immunohistochemical localization of core proteins
For the immunohistochemical localization of core proteins, the same 
protocol as for the localization of GAG domains was used, but with 
omission of the anti-VSV antibodies. Antibodies used were anti-versican 
(12C5, Development Studies Hybridoma bank, 1:50), anti-perlecan 
(Chemicon, Temecula, California, USA, 1:10,000), anti-agrin (UBI, Lake 
Placid, New York, USA, 1:20), anti-endostatin (the c-terminal part of type 
XVIII collagen) (Alpha Diagnostic International, San Antonio, USA, 1:100), 
anti-syndecan-1 (CD138, Serotec Inc, Oxford, UK, 1:100), -2 (10H4, 1:500) 
and -3 (1C7, 1:50). Antibodies were visualised using Alexa-488 or –594 
conjugated secondary antibodies.  
A confocal microscope (Biorad MRC1024) and a routine immunofl uorescence 
microscope (Zeiss Axioskop) were used to analyze the sections. Two 
observers (J.F.M.L. and A.R.) analyzed the stainings double blind.
Immunoelectron microscopy
Human kidney biopsies were fi xed for 3 hours in Somogyi solution containing 
4% formaldehyde and 0.05% glutaraldehyde in 0.1M phosphate buﬀ er (PB). 
200 μm Sections were cut using a vibratome and incubated in increasing 
amounts of glycerol (10-20-30%) in PB for 30 min. Sections were oriented 
on Thermanox (LAB-TEK DVI., Miles Laboratories Inc., Naperville) and 
rapidly frozen in liquid propane (–190C), using a rapid freeze apparatus 
(KF80, Reichert-Jung, Germany). Freeze substitution was performed as 
described22. Ultrathin lowicryl HM20 resin sections were cut on a Reichert 
Ultracut-E and mounted on one-hole nickel grids coated with a formvar fi lm. 
Sections were pre-incubated in PBS containing 0.2% BSA and 0.05% cold 
fi sh skin gelatin (PBG). Sections were incubated overnight at 4C in drops 
of PBG containing anti-GAG scFv antibodies, diluted 1:100, and washed 
for 20 min in PBG. Bound antibodies were visualized using anti-VSV tag 
antibody P5D4 and goat anti-mouse IgG labeled with gold spheres (10 nm, 
Aurion, Wageningen, Netherlands). Sections were washed in PBS and post-
fi xed with 2.5% glutaraldehyde in PBS for 5 min. After washing with distilled 
water, sections were contrasted with uranyl acetate and studied using a Jeol 
TEM 1010 electron microscope.
Involvement of HS domains in FGF-2 handling
1. Binding of FGF-2 to HS
To study whether FGF-2 (produced, isolated and purifi ed as described 
before23)  binds to HS two strategies were employed. 
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In the fi rst strategy cryosections were incubated with and without FGF-2 
(10 μg/ml PBS containing 1% Tween (PBST)) for 1 hour, and subsequently 
stained for HS domains using scFv antibodies (see above). It was evaluated 
whether staining intensity was reduced. In addition, cryosections were, 
prior to incubation with FGF-2, incubated for 2 hours with 0.04 IU 
heparinase III (IBEX Technologies, Montreal, Quebec, Canada) in 25mM 
Tris/HCl pH 8 at 22˚C. Thereafter, the capacity to bind FGF-2 was evaluated 
by immunofl uorescence using an anti-FGF-2 antibody (F-3393, Sigma-
Aldrich, St Louis, USA) and Alexa 488-conjugated goat anti-mouse IgG. 
In the second approach the eﬀ ect of purifi ed scFv antibodies on FGF-
2 binding to human mesangial cells in culture was studied. SV40 large 
T antigen-immortalized human mesangial cells (HMCs) were used  as 
described before24, and grown in Dulbecco’s modifi ed Eagle’s medium 
(DMEM) (Invitrogen, Breda, The Netherlands) with 5.5 mM glucose 
and 10% heat inactivated fetal calf serum gold (FCS) (PAA, Pasching, 
Austria) at 37˚C, unless stated otherwise. Passages 5 to 8 were used for 
the experiments. Cells were evaluated for the expression of mesangial 
cell markers, positive ones (smooth muscle actin, fi bronectin, vimentin, 
desmin), as well as negative ones (cytokeratin 18, CD45). Results were the 
same as found by B. Banas24. In 24-well plates (Greiner, Alphen a/d Rijn, 
The Netherlands), human mesangial cells were seeded on glass coverslips 
at a density of 50,000 cells/well. After 24 hours of adjusting, the cells were 
washed twice with PBS and once with DMEM containing 0.5% FCS. Cells 
were then incubated for 5, 30, 60 minutes and 24h in DMEM containing 
100 μg purifi ed scFv antibodies/ml DMEM containing 0.5% FCS, followed 
by incubation for 1 hour in DMEM containing FGF-2 (10 ng/ml). Cells 
were fi xed using ice-cold methanol and stained with scFv antibodies as 
described, or with the anti-FGF-2 antibody followed by goat anti-mouse 
Alexa 488. To evaluate HS dependency of scFv antibody binding as well as 
FGF-2 binding, cells were pretreated with heparinase III (see above).  
2. Involvement of HS domains in FGF-2-induced cell proliferation
To evaluate the eﬀ ect of the scFv antibodies on the FGF-2-induced 
proliferation, human mesangial cells were seeded in a 96 well-plate 
(Greiner, Alphen a/d Rijn, The Netherlands) (10,000 cells/well) in DMEM 
containing 5.5 mM glucose and 0.5% FCS. Cells were incubated at 37˚C 
with and without purifi ed scFv antibodies as described above, and FGF-2 
(10 ng/ml) was added 5 minutes thereafter. Incubation was for 4 days. Cell 
proliferation was analyzed using the WST-1 test, based on the conversion 
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of the substrate WST-1 by mitochondrial dehydrogenases of viable cells 
to a soluble formazan salt, which directly correlates with the cell number 
(Roche Diagnostics GmbH, Penzberg, Germany). Absorbance was read at 
450nm.
Table 3. Distribution of GAG domains in the normal human kidney as detected by 
scFv antibodies against heparan or chondroitin sulfate
Stain ing: ++, strong; +, good; ±, moderate; and –, absent. 
* Parts of the tubule stained positive.
Results 
Localization of GAG domains
Immunofl uorescence microscopy
The distr ibution of GAG domains in human kidney is summarized in Table 
3. Heparinase III treatment abolished all HS staining (data not shown). HS 
domains were restricted to basement membranes or cell surfaces, while the 
CS domain primarily localized to the interstitium (see Figs. 1-2, Table 3). Of 
the anti-HS scFv antibodies, HS4C3 predominantly stained the mesangial 
areas and peritubular capillaries, but also showed staining of the glomerular 
basement membrane (Figs. 1-3, Table 3). The domain recognized by HS4E4 
was primarily present in Bowman’s capsule and the collecting ducts (Fig. 
1, Table 3). ScFv antibody AO4B08 most strongly stained the collecting 
ducts and smooth muscle cells, but there was also good staining of the 
descending and ascending thin limbs of Henle’s loop (Fig. 2, Table 3), and 
Bowman’s capsule. RB4Ea12 only showed good staining of the proximal 
tubules (Fig. 1, Table 3). EW4A11 moderately stained all structures within 
the glomerulus and the thick ascending limb, but also showed clear staining 
of the rest of the tubules (Table 3). EW3D10 displayed a strong staining of 
the collecting ducts, and an evident staining of the glomerular tuft, the 
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mesangium, peritubular capillaries and the connecting tubules (Figs. 1-2, 
Table 3). 
IO3H10, the anti-CS scFv antibody, stained the proximal tubules and the 
thick ascending limbs, as well as Bowman’s capsule and blood vessel 
endothelium (Fig. 2, Table 3). The staining patt ern was more fi brillar, in 
contrast to the linear patt ern seen using the HS antibodies. 
To study co-localization of specifi c GAG domains with specifi c 
proteoglycans we analyzed the distribution of 7 diﬀ erent core proteins in 
the kidney (Table 4). Although partial overlap was noticed in a number of 
cases, no complete overlap was observed between any of the specifi c GAG 
domains with any of core proteins studied. 
Figure 1. Immunostaining for HS domains in the normal human glomerulus using 
four diﬀ erent anti-GAG scFv antibodies. Cryosections were incubated with periplasmic 
fractions of bacteria containing the antibodies. The antibodies shown are HS4C3 (A), HS4E4 
(B), RB4Ea12 (C) and EW3D10 (D). G: glomerulus. Bar, 50 μm. 
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Figure 2. Immunostaining for GAG domains in normal human renal tubules using anti-
GAG scFv antibodies. Cryosections were incubated with periplasmic fractions of bacteria 
containing the antibodies. The left panels show the anti-HS scFv antibody, the middle panels 
the tubule-specifi c markers, and the right panels the merged image. The antibodies shown 
are EW3D10 (A1-A3), AO4B08 (B1-B3), HS4C3 (C1-C3) and IO3H10 (D1-D3). The tubule 
specifi c antibodies used are Tamm Horsfall (A2 & D2), Aquaporin 3 (B2) and Aquaporin 1 
(C2). TAL: thick ascending limb; CD: collecting duct; PT: proximal tubule; DTL: distal thick 
limb. Bar, 50 μm.
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Figure 3. Immunostaining for exogenously applied FGF-2 (A) and HS4C3 (B) in the normal 
human glomerulus. Bar, 50 μm.
Table 4. Distribution of proteoglycan core proteins in the normal human kidney.
Staining: ++, strong; +, good; ±, moderate; and –, absent. 
* C-terminal fragment of type XVIII collagen.
Immunoelectron microscopy
Four antibodies (HS4C3, EW3D10, HS4E4, and EW4A11) were selected 
for the ultrastructural localization of specifi c HS domains, with special 
emphasis on the glomerulus. The scFv antibody HS4C3 stained the GBM 
at the site of the podocytes, but not of the endothelium (fi g. 4A). It also 
stained the mesangial cells within the glomerulus, but not Bowman’s 
capsule (data not shown). In contrast, antibody EW3D10 primarily stained 
the cell surface of the podocytes, rather than the GBM (fi g. 4B). Antibody 
HS4E4 did not show any staining in the glomerulus (fi g. 4C), but it did 
react with the basal lamina of Bowman’s capsule. With antibody EW4A11 
no major labelling was observed in the glomerulus.
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Figure 4. Immuno-electron microscopical staining for HS domains in the normal human 
glomerulus using anti-HS scFv antibody HS4C3 (A), EW3D10 (B), HS4E4 (C) and the non-
relevant scFv antibody MPB59 (D). The HS domain defi ned by HS4C3 is present in the GBM 
at the site of the podocytes, whereas the domain defi ned by EW3D10 is primarily present at 
the cell surface of the podocytes (arrows in B). Domain HS4E4 is absent in the glomerulus. 
Bar, 250 nm.
Involvement of HS domains on FGF-2 handling
Staining for endogenous FGF-2 in normal human kidney sections revealed 
only faint staining of FGF-2. Therefore, kidney cryosections were loaded 
with FGF-2. FGF-2 primarily bound to the mesangium, to the glomerular 
tuft and to a lesser extent to Bowman’s capsule (Fig. 3A). The ascending thin 
limbs of Henle’s loop, and the collecting ducts were also positive for FGF-
2 staining. This is in line with observations done by others25. FGF-binding 
to sections was heparinase III sensitive, indicating that HS is involved in 
FGF-2 binding. 
To study the involvement of specifi c HS domains in FGF-2 handling, we 
selected two scFv antibodies: HS4C3 and RB4Ea12. In a previous study19, 
using an ELISA approach, it was shown that the domain defi ned by scFv 
antibody HS4C3 was involved in FGF-2 handling, since FGF-2 was able to 
inhibit the binding of scFv antibody HS4C3 to immobilized HS by 59%. 
Since the HS4C3 antibody also strongly stained the mesangial area, the site 
where most FGF-2 staining was found (Fig. 3), we selected this antibody 
for further study using a functional, cell culture, approach. We also selected 
scFv RB4Ea12, since this antibody did not stain the mesangium (Fig. 1, 
Table 3), and FGF-2 did not inhibit binding of this antibody to immobilized 
Chapter 3
72
HS (data not shown). Both scFv antibodies, however, do stain HMCs cells in 
vitro (Fig. 5 A1-2). As a control scFv antibody MPB59 was used (Fig. 5 C3). 
This antibody shows, on an amino acid basis, 99% similarity with HS4C3, 
but is not reactive with HMCs or HS (Fig. 5 C3). 
To study whether FGF-2 is bound to HMCs by HS, cells were loaded with 
FGF-2 with and without prior treatment with heparinase III. As can be seen 
form Figure 5 B3, FGF-2 binding is heparinase sensitive: no FGF-2 was 
bound by HMCs after enzymatic removal of HS. To study the eﬀ ect of FGF-2 
on HMCs, fi rst the stimulatory eﬀ ect of FGF-2 was assessed using the WST-
1 assay (Fig. 6). It was found that 10 ng/ml FGF-2 had a stimulatory eﬀ ect 
on HMC proliferation compared to cells grown without exogenous FGF-
2 (control). The stimulatory eﬀ ect of FGF-2 was completely counteracted 
by prior addition of HS4C3, but not by prior addition of RB4Ea12 or 
MPB59 (Fig. 6). Addition of the scFv antibody alone had no eﬀ ect on HMC 
proliferation (Fig. 6). Prior addition of HS4C3, but not prior addition of 
RB4Ea12 or MPB59, prevented FGF-2 to bind to HMCs (Fig. 5 C1-3).  
Figure 5. Immunostaining of human mesangial cells. A1-3 shows cells grown in presence of 
scFv antibodies HS4C3, RB4Ea12, and of FGF-2 respectively. Cells were stained for presence 
of the scFv antibodies (A1-2, B1-2) or for FGF-2 (A3, B3). In B1-3, cells were pretreated with 
heparinase III (HepIII) and subsequently treated as A1-3. C1-3 shows mesangial cells grown 
in presence of both a scFv antibody and FGF-2, and stained for FGF-2. Note that antibody 
HS4C3, but not RB4Ea12, inhibits binding of FGF-2 to mesangial cells. MPB59 is a non-
relevant scFv antibody that serves as control (C3). Bars, 20 μm (A & C); 50 μm (B).
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Figure 6. Eﬀ ect of FGF-2 and purifi ed scFv antibodies, alone or together, on human 
mesangial cell proliferation. Proliferation was measured at 450nm using the WST-1 test. 
Incubation conditions of the cells are depicted on the x-axis, % proliferation on the y-axis. 
Proliferation of mesangial cells without FGF-2 and scFv antibody was taken as 100%. Note 
that only antibody HS4C3 is capable of inhibiting the proliferative eﬀ ect of FGF-2.
Discussion
This study shows that there are many diﬀ erent GAG domains located in 
the adult human kidney. Each domain has a characteristic distribution in 
the kidney and especially in the nephron. The HS domains are confi ned to 
the basement membranes and cell surfaces, whereas the CS domain was 
abundantly expressed in the interstitium, but not in the mesangial area. 
Since 7 diﬀ erent scFv antibodies were used, the results indicate that there 
are at least 7 diﬀ erent HS chains in the kidney. Domain heterogeneity 
within a single chain of HS is also highly likely1;26. Therefore, in the 
kidney an extensive set of diﬀ erent HS domains is present. We studied 
whether there was a co-localization of a specifi c core protein and one of 
the scFv antibodies. Ultrastructural studies indicated some domains to be 
associated with basement membrane proteoglycans (e.g. domain defi ned 
by antibody HS4C3, present in the GBM), and others with cell surface 
proteoglycans (e.g. domain defi ned by antibody EW3D10, present at 
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the cell surface of podocytes). However, there was no complete overlap 
between any of the domains defi ned by the scFv antibodies and a specifi c 
core protein. One explanation for this is that a specifi c core protein can 
be substituted with diﬀ erent GAG chains depending on the type of cell 
(podocyte, endothelium, tubular epithelium etc.) and its physiological 
state27. In addition, splice variants of core proteins may infl uence the GAG 
moiety present in proteoglycans. Immunoprecipitation studies may reveal 
the core protein(s) to which a specifi c GAG domain is bound. The location 
of the domain defi ned by HS4C3 in the GBM just below the foot processes 
of the podocytes is of interest regarding the barrier function of the HSPGs 
in the GBM. The antibody recognizes a highly sulfated HS domain and 
may therefore be directly involved in the charge-dependent permeability 
characteristics of the glomerulus. 
Heparan sulfates bind and modulate a vast amount of proteins (“heparin-
binding proteins”)2;26. These include growth factors like FGF’s and VEGF’s, 
chemokines like the CXC and CC types, matrix molecules like collagens 
and laminins, enzymes like proteases and lipases, and various enzyme 
inhibitors (e.g. serpins), receptor proteins (e.g. growth factor receptors) 
and viral/bacterial proteins. Many of these proteins play an important role 
in the kidney during health and disease. It is becoming increasingly clear 
that the protein-binding characteristics of HS cannot be ascribed to a few 
generic HS molecules, but that instead many HS species, each with typical 
domain structures, exist. A major question is what the cell biological 
relevance of the various specifi c domains is. To address this question, we 
studied the biological importance of two domain structures (defi ned by scFv 
antibodies HS4C3 and RB4Ea12) with respect to the proliferative eﬀ ect of 
FGF-2 on human mesangial cells. We, and others, have shown that FGF-2 is 
a potent stimulator of these cells28. It was found that the HS4C3, but not the 
RB4Ea12 domain is involved in the binding and handling of FGF-2. ScFv 
antibody HS4C3 recognizes highly sulfated HS structures containing O- as 
well as N-sulfated disaccharides19. RB4Ea12, on the other hand, recognizes 
low-sulfated oligosaccharides, and 2-O sulfation impedes binding. This is 
in line with what is known about the structural requirements in the HS 
domain necessary for FGF-binding, in which a 2-O sulfated iduronic acid 
residue is essential. HS has a role in binding both FGF-2 and its receptor 
(transmembrane tyrosine kinase receptor)3;29;30. For renal interstitial 
fi broblasts the response to FGF-2 is HS mediated31. Binding of HS to the 
receptor is dependent on 6-O sulfation, and consequently 2- as well as 
6-O sulfation is needed to initiate the signalling events. HS chains, which 
contain multiple FGF-2 binding sites, may bring together FGF-2’s and their 
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receptors in a three-dimensional patt ern, such that dimerization, necessary 
for signal transduction, is established3;30;32. An eﬀ ect of the antibodies as 
such on the signalling events is unlikely since scFv are monovalent and 
the binding of antibody RB4Ea12 to HMCs did not result in any eﬀ ect. The 
HS4C3 domain is primarily located in the mesangium, and exogenously 
applied FGF-2 also concentrates, in a HS-dependent way, in this area. This 
indicates that in vivo, the kidney may use this HS domain to sequester FGF-
2 in the mesangium. FGF-2 is involved in a number of renal pathologies 
including mesangioproliferative glomerulonephritis33, tubulointerstitial 
scarring34, dysplasia35, and hemolytic uremic syndrome36. A specifi c, FGF-2 
binding HS domain, defi ned by antibody 10E4, was found associated with 
fi brotic lesions of the peritubular interstitium, further indicating that HS 
chains with a specifi c domain structure are involved in FGF-2 handling37. 
Knowledge of the chemical structure of HS oligosaccharides involved 
in FGF-2 handling may lead to the development of glycomimetica for 
therapeutic use. In this respect an analogy may be drawn to the development 
of highly active anti-coagulative oligosaccharides38. The synthesis of 
these drugs was based on the identifi cation of the chemical structure of a 
pentasaccharide involved in the binding of HS/heparin to anti-thrombin III. 
HS/heparin preparations like sulodexide and danaparoid have been found 
to be clinically eﬀ ective in ameliorating micro- and macroalbuminuria 
in diabetic nephropathy39-42. In patients with diabetes, with and without 
nephropathy, the amount of N-sulfation (as indicated by reactivity with 
antibody 10E4) was found to be decreased in the urine as well as in the 
kidney43. Using the set of scFv antibodies applied in this study further 
information can be gathered on structural alterations in HS associated with 
diabetic nephropathy, eventually leading to a bett er understanding of the 
various stages of diabetes and perhaps in bett er treatment. In addition, 
and because the antibodies used in this study are of a human nature (the 
phage display library was constructed using human germ line genes), the 
antibodies may be applied in immunotherapy. Antibodies against FGF-2 
have been shown to reduce mesangial cell injury and proliferation in a rat 
model for mesangial proliferative glomerulonephritis33. 
Some of the scFv antibodies used have also been applied for staining of 
rat kidney19-21. In general a good correlation in staining patt ern is seen 
in human and in rat kidneys, indicating a tight control of HS domain 
expression. However, some diﬀ erences are notable. For instance, scFv 
antibody HS4E4 stained peritubular capillaries in rat, but not in human 
kidney. Diﬀ erences may be accounted for by variations between species. 
However, they may also be due to diﬀ erences in age. The rats used were 
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three months of age (young adults), whereas the human kidneys were 
from middle-aged individuals (mean 51 years). In human aorta an increase 
in HS 6-O-sulfation with age has been observed44, and implicated in the 
increased binding of platelet-derived growth factor to HS. Age-induced 
alterations in HS structure may also (functionally?) occur in the kidney and 
could be demonstrated by the anti-HS scFv antibodies.
In conclusion, a number of structurally diﬀ erent GAG domains with a 
specifi c location are present in the normal human kidney, and are likely 
involved in physiological phenomena. Future research will focus on the 
chemical identifi cation of the diﬀ erent domains and their role in renal 
pathobiology.
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Abstract
Dermatan sulfate (DS) is a member of the glycosaminoglycan (GAG) family 
and is primarily located in the extracellular matrix. Using a modifi ed phage 
display procedure, we selected 2 diﬀ erent antibodies against DS of which 
one antibody, LKN1, was specifi c for DS. LKN1 was especially reactive 
with 4/2,4-di-O-sulfated DS, and did not react with other classes of GAGs 
including chondroitin sulfate and heparan sulfate. Immunohistochemical 
analysis of kidney, skin and tendon showed a typical fi brillar staining 
patt ern, co-localizing with type I collagen. Staining was abolished by 
specifi c enzymatic digestion of DS. Immunoelectron microscopy confi rmed 
the association of the DS epitope with collagen fi brils. The location of DS 
did not follow the main banding period of collagen, which is in line with 
the current concept that the core protein rather than the DS moiety of DS-
proteoglycans specifi cally binds to collagen fi brils. This unique anti-DS 
antibody and the availability of its coding DNA may be instrumental in 
studies of the structure and function of DS.
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Introduction
Dermatan sulfate (DS) is a member of the glycosaminoglycan (GAG) 
family of structurally complex, sulfated, linear polysaccharides. DS is a 
copolymer of N-acetyl galactosamine (GalNAc) and iduronic acid (IdoA)/
glucuronic acid (GlcA) residues. In DS, in contrast to chondroitin sulfate 
(CS), the glucuronic acid moiety is (partially) epimerized to iduronic acid. 
DS is covalently bound to a core protein to form a proteoglycan, such as 
decorin and biglycan 1. Both biglycan and decorin play distinct roles in the 
synthesis and deposition of collagen fi brils. Disruption of the decorin gene 
in mice leads to fragile skin and altered collagen fi bril morphology, whereas 
biglycan defi ciency also results in structural abnormalities of collagen 
fi brils in bone, dermis and tendon, indicating a fundamental role of DS 
proteoglycans in regulating collagen fi bre formation in vivo2, 3. DS infl uences 
the mechanical strength of collagen fi brils in vitro4 and has been implicated 
in a number of processes including development, growth, wound repair, 
growth factor binding, coagulation and tumorigenesis1. The biosynthesis 
of DS allows for extensive structural heterogeneity within a single chain 
and between chains. The uronic acid can be either GlcA or IdoA, with or 
without 2-O-sulfation, whereas the galactosamine can be non, 4-, and/or 
6-O-sulfated. This results in 24 possible combinations for each disaccharide 
unit. Given an average number of 40–100 disaccharides in a single DS 
chain, a vast number of diﬀ erent DS chains, each with unique disaccharide 
sequences, can be generated. Antibodies are obvious tools to study the 
diversity and distribution of DS. Some antibodies recognizing both DS and 
CS have been described5. Recently, one specifi c anti-DS antibody (2A12) 
was reported using 2,6-di-O-sulfated DS from Ascidia nigra as the antigen6. 
In general, due to the poor immunogenic nature of GAGs, it is diﬃ  cult 
to obtain specifi c antibodies directed against glycosaminoglycans. The 
antibody phage display system allows the selection of antibodies against 
non-immunogenic molecules, since it does not discriminate between “self” 
and “non-self” antigens. In addition, the cDNA encoding the antibody 
becomes readily available. In this study we used a semi-synthetic antibody 
phage display library to select antibodies to DS. 
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Materials and methods
Selection of dermatan sulfate-binding antibodies
The antibody phage display technique was used as described 7, 8. Briefl y, 
tubes were coated with porcine skin DS (Seikagaku Kogyo Co, Tokyo, 
Japan), and biopanning was performed using antibody displaying phages 
from a human semi-synthetic single chain variable fragment library 9. 
Phages were allowed to bind to immobilized DS for 2 h under rotation. 
Nonbound phages were washed away and bound phages were eluted with 
1 ml 100 mM triethylamine for 10 or 20 min under rotation. The eluate was 
neutralized by addition of 0.5 ml 1 M Tris–HCl (pH 7.3). Four rounds of 
biopanning were performed. A synthetic medium (synthetic broth AOAC 
(Association of Oﬃ  cial Analytical Chemists; Sigma-Aldrich, St. Louis, MO)) 
was used during the selections, rather than the 2xTY medium previously 
described, since the latt er contained DS. 
Determination of antibody reactivity by ELISA 
Reactivity of the antibodies with immobilized GAGs was evaluated using 
ELISA as described7. In addition, a competition ELISA was performed 
using a number of test molecules, with DS immobilized onto the microtiter 
plate. The IC50 values representing the amount of test molecule necessary 
to inhibit 50% of the antibody binding were established. Test molecules 
included: chondroitin 4-sulfate (CSA from sturgeon notochord), chondroitin 
6-sulfate (CSC from shark cartilage), 2,6-di-O-sulfated chondroitin sulfate 
(CSD from shark cartilage), 4,6-di-O-sulfated chondroitin sulfate (CSE 
from squid cartilage), and dermatan sulfate (DS from porcine skin), all 
from Seikagaku Kogyo Co, Tokyo, Japan, DS (from porcine intestinal 
mucosa, Celsus laboratories inc., Cincinnati, OH), 4/2,4-di-O-sulfated DS 
(4/2,4-DS from Styela plicata, which is about 28% 4-O-sulfated and 66% 
2,4-di-Osulfated10) and 2,6-di-O-sulfated DS (2,6-DS from Ascidia nigra11), 
and heparan sulfate (HS, from intestinal mucosa), dextran sulfate, calf 
thymus DNA and hyaluronate all from Sigma-Aldrich, St Louis, USA. A 
mouse anti-VSV antibody (P5D4, culture supernatant) was used to detect 
the bound anti-DS antibodies. 
Immunohistochemical staining
Light and electron microscopical stainings were performed as described 
before12. Reactivity of the antibody was evaluated on kidney sections with 
and without treatment of glycosidases, including heparinase III (cleaves 
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HS, IBEX Technologies, Montreal, Quebec, Canada), chondroitinase ABC 
(cleaves CS and DS) and chondroitinase B (cleaves DS) from Sigma-Aldrich, 
St Louis, USA. Immunohistochemistry was also performed on pharynx 
sections of the ascidians Styela plicata and Ascidia nigra, which contain high 
amounts of 4/2,4-DS, and 2,6-DS, respectively 13, 14, and on mouse skin and 
rat tendon. 
Figure 1. Reactivity of antibody LKN1 (ELISA) with various immobilized molecules (A), 
or with molecules in solution (B). In A, reactivity is given relative to DS which was set at 
100%. In B, reactivity is given as IC50 values representing the amount of molecule which 
results in a 50% inhibition of antibody binding to immobilized DS. HS, heparan sulfate; 
CSA,C,D,E, chondroitin sulfate A,C,D,E; DS, dermatan sulfate; 4/2,4-DS, 4/2,4-di-O-
sulfated DS; 2,6-DS, 2,6-di-O-sulfated DS; KS, keratan sulfate; –, IC50>5000 ng/ml.
Results and discussion 
Initial att empts to select anti-DS antibodies using the phage display 
technique were not successful. Analysis of the bacterial medium used, 
indicated that the yeast extract present in the standard 2xTY medium 
contained signifi cant amounts of DS, making it impossible to select anti-
DS antibodies. Therefore, a synthetic medium not containing GAGs was 
applied for the selection of specifi c anti-DS antibodies. After introducing 
this medium, 2 anti-DS antibodies, LKN1 and LKN6, were selected. Both 
antibodies belonged to the VH1 family, LKN1 having the germ line segment 
DP25 and a VH CDR3 sequence of GIKL, and LKN6 having the germ line 
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segment DP14 and a VH CDR3 sequence of SRMRNMQRMDF. Antibody 
LKN1 exclusively recognized DS, whereas antibody LKN6 recognized both 
HS and DS. Antibody LKN1 was used for further characterization. LKN1 
reacted with immobilized DS, 2,6-DS, and especially with 4/2,4-DS, but 
not with HS, CSA, CSC, CSD, CSE, KS, dextran sulfate, calf thymus DNA 
and hyaluronate (Fig. 1A). The absence of reactivity with CSA (primarily 
4-O-sulfated) compared to DS (primarily 4-O-sulfated) indicated that 
LKN1 needs IdoA for binding (CSA does not contain IdoA). This was 
further substantiated by the reactivity of the antibody with 2,6-DS, but not 
with its non-epimerized counterpart CSD. The marked increase of LKN1 
binding to 4/2,4-DS compared to DS is probably due to the presence of the 
2-O-sulfate in the fi rst, indicating the recognition of 2-O-sulfation in DS.
Figure 2. Immunohistochemical staining of the pharynx of Ascidians using anti-DS 
antibodies LKN1 and 2A12. In the pharynx of the Styela plicata (S. plicata), rich in 4/2,4-di-
O-sulfated DS, staining is strong with antibody LKN1 (A), but not with antibody 2A12 (B). In 
the pharynx of the Ascidia nigra (A. nigra), rich in 2,6-di-O-sulfated DS, there is no staining 
with antibody LKN1 (C), in contrast to antibody 2A12 (D). Bar=50 μm.
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To further study the specifi city of the antibody, inhibition ELISA’s were 
performed (Fig. 1B). Antibody LKN1 was reactive with DS and especially 
with 4/2,4-DS (IC50 values of 139 and 52 ng/ml, respectively), whereas 
other molecules were not reactive (IC50 values>5000 ng/ml). Specifi city was 
also evaluated using immunohistochemistry (Fig. 2). The LKN1 antibody 
reacted strongly with 4/2,4-DS containing pharynx of the S. plicata (Fig. 2A), 
whereas it showed litt le reaction with 2,6-DS containing pharynx sections 
of the A. nigra (Fig. 2C). The LKN1 antibody diﬀ ers from the recently 
reported 2A12 anti-DS antibody6, which does not react with pig skin DS 
or 4/2,4-DS in the S. plicata (Fig. 2B), but specifi cally recognizes the 2,6-di-
Osulfated DS as present in the A. nigra (Fig. 2D). In mammalian tissues, a 
fi brillar staining patt ern was seen using antibody LKN1. In the human as 
well as in rat kidney it was present in the interstitial spaces between the 
tubules and in Bowman’s capsule (Fig. 3A). Pre-treatment of cryosections 
with chondroitinase ABC or B (Fig. 3B) completely abolished staining of 
the antibody, whereas heparinase III treatment had no eﬀ ect (Fig. 3C),
Figure 3. Light and electron microscopical immunostaining using anti-DS antibody 
LKN1. In the kidney, a fi brillar staining was observed e.g. in the peritubular interstitium (A), 
co-localizing with staining for type I collagen (D). Immunoelectron microscopy indicated 
association with collagen fi brils, but not with basement membranes (E, F). Staining was 
abolished by pre-treatment of kidney sections with the glycosidase chondroitinase B (B), 
but not with heparinase III (C). T: renal tubule; I: tubular interstitium; G: glomerulus; B: 
Bowman’s capsule; C: collagen fi bril; BM: basement membrane. Bar=50 μm (A–D), 250 nm 
(E, F).
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further indicating that LKN1 specifi cally recognized DS. Using double 
staining with an antibody against type I collagen, a strong co-localization 
was observed in kidney (Fig. 3A, D), in tendon and in skin (Fig. 4A–D). This 
was further supported by immunoelectron microscopy, where the LKN1 
antibody staining co-localized with collagen fi brils (Fig. 3E, F). A distinct 
periodic banding patt ern, as seen with antibodies against the core protein 
of the DSPG decorin 1, 15, was not observed, further indicating that DS 
rather than the core protein was recognized by LKN1. This staining patt ern 
supports current models for the interaction of collagen fi brils with decorin, 
in which the core protein specifi cally binds to collagen fi brils according 
to their main banding patt ern, and the DS moiety is located between the 
fi brils16- 19. Antibody LKN1 did not react with basement membranes (Fig. 
3F), indicating that it did not react with type IV collagen or basement 
membrane-bound GAGs. In conclusion, we selected a unique antibody 
that specifi cally recognizes a collagen-associated DS epitope. The antibody, 
together with the availability of its coding DNA, may be instrumental in 
studies to the structure and function of DS in health and disease. 
Figure 4. Immunohistochemical staining of skin and tendon using anti-DS antibody 
LKN1 and anti-type I collagen. In both the skin (dermis, DER) and the tendon colocalization 
of the LKN1 antibody (A–B, respectively) with staining for type I collagen (C–D) can be seen. 
Also note co-localization in skeletal muscle (M). Bar=50 μm.
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Abstract
Dermatan sulfate (DS), also known as chondroitin sulfate B, is a member 
of the linear polysaccharides called glycosaminoglycans (GAGs). DS plays 
a role in collagen fi bril formation and strength, and is involved in various 
processes, such as wound healing and fi brosis. DS is capable of binding 
and modulating the activity of a myriad of factors, including fi broblast 
growth factor (FGF)-1, -2 &-7, heparin cofactor II and interferon (IFN)-γ. 
The recent development and description of two new DS specifi c antibodies 
oﬀ ers the possibility to further study this class of GAGs, focussing on 
domain structures defi ned by the antibodies. 
We studied the staining patt ern of DS using the anti-DS antibodies LKN1 
and GD3A12 in normal renal tissue, and in kidney biopsies obtained 
from patients, with acute interstitial or vascular renal allograft rejections, 
patients with chronic allograft nephropathy (CAN), and from patients with 
focal segmental glomerulosclerosis (FSGS), membranous glomerulopathy 
(MGP) or systemic lupus erythematosus (SLE).
Expression of the 4/2,4-di-O-sulfated DS domain primarily recognized by 
the LKN1 antibody was decreased in the interstitium of transplant kidneys 
with CAN, while its expression was increased in the interstitium in FSGS, 
MGP and SLE. The decreased expression of the 4/2,4-di-O-sulfated DS 
domain was accompanied by an increased expression of type I collagen in 
CAN. Importantly, glomerular LKN1 staining was not observed in controls, 
while patients with diﬀ erent forms of renal allograft rejections and with 
glomerular diseases showed a glomerular LKN1 staining. Expression of 
the IdoA-Gal-NAc4S DS domain primarily recognized by GD3A12 was not 
diﬀ erent between controls, patients with diﬀ erent forms of renal allograft 
rejections and patients with glomerular diseases, for either the tubular 
interstitium or the glomerulus. These data indicate a role for the DS domain 
recognized by antibody LKN1 in renal diseases with early fi brosis, which 
may lead to the development of new and earlier screening possibilities for 
these diseases.
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Introduction
Dermatan sulfate (DS) is a member of the large family of linear 
polysaccharides called glycosaminoglycans (GAGs). DS is also known as 
chondroitin sulfate B (CS-B) and is composed of repeating disaccharide 
units consisting of N-acetyl galactosamine (GalNAc) and glucuronic acid 
(GlcA) residues. The presence of the epimerized form of GlcA, iduronic 
acid (IdoA), defi nes it as DS. Covalently bound to a core protein DS forms 
proteoglycans (PGs), such as decorin (DCN) and biglycan (BGN)1. The 
level of complexity of DS is dictated by a variable structure and chain 
length of up to 40-100 disaccharide units. The uronic acid can be either a 
GlcA or IdoA with or without 2-O-sulfation, and the GalNAc residue can 
be 4- and/or 6-O-sulfated. These possibilities can result in the formation of 
several defi ned disaccharide units; CSA (4-O-sulfated), CSB/DS (IdoA and 
4-O-sulfated), CSC (6-O-sulfated), CSD (2,6-di-O-sulfated), CSE (4,6-di-O-
sulfated) and CSEi (IdoA and 4,6-di-O-sulfated)2.
 DS is able to bind a myriad of factors, including fi broblast growth 
factor (FGF)-1, -2 &-7, heparin cofactor II and interferon (IFN)-γ1. Specifi c 
sulfation patt erns and the amount of epimerization within a CS/DS chain 
dictate growth factor binding and function, such as cell proliferation, signal 
transduction and extracellular matrix (ECM) modulation1. The biological 
roles of both the proteoglycan core protein and the DS side chains have 
been studied, mostly in relation to other extracellular matrix components, 
especially collagens. These studies have indicated fundamental roles of 
the DSPGs BGN and DCN in regulating collagen fi bril formation in vivo3;4, 
while the DS side chains have been implicated in infl uencing the mechanical 
strength of collagen fi brils in vitro as well5. An increase in extracellular 
matrix and collagen is related to fi brosis and sclerosis. 
 Glomerulosclerosis and tubulointerstitial fi brosis are common 
pathological features of most end-stage kidney diseases irrespective of the 
underlying etiology6. It is also the fi nal common pathway of renal allograft 
damage, where the specifi c features are interstitial fi brosis and tubular 
atrophy, which can lead to glomerulosclerosis resulting in a decline in 
glomerular fi ltration rate7. Renal allograft injury can roughly be divided as 
acute, mediated by cellular and/or antibody mediated rejection or chronic, 
with moderate to severe interstitial fi brosis, tubular atrophy and absence of 
specifi c glomerular pathology in an early stage8. Tubulointerstitial fi brosis 
involves infl ammation, proliferation, apoptosis and fi brosis. An early 
identifi cation of renal allograft loss could improve long-term allograft 
survival. Both acute and chronic rejections are associated with increased 
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chemokine expression, many of which are GAG-binding9. There is an 
increase in circulating GAGs in patients with acute allograft rejection10 
and experimental heparin/synthetic sulfated oligosaccharides therapy 
has been shown to prolong transplant function and reduce rejection11;12. 
In a recent paper by Rienstra et al.9 it was shown that the heparan sulfate 
(HS) PG expression was increased in sclerotic glomeruli, while the CSPG 
expression was increased in the fi brotic interstitium in a renal transplant 
model in rats. CS/DS and DSPGs have been reported to be increased in 
several fi brotic renal diseases, including interstitial fi brosis, diabetic 
nephropathy, mesangial sclerosis and nephrosclerosis13;14. Changes in CS/
DS content and modifi cations have been found in diﬀ erent animal models 
for renal disease. In the unilateral urethral obstruction (UUO) model in the 
rat, a model for renal interstitial fi brosis, fi brotic lesions showed ten-fold 
increase in CS/DS content and a decrease in the sulfation degree of CS/DS, 
accompanied by a lower IdoA content14. There was also an increase in CS/
DSPGs, collagen and fi bronectin in the UUO model15. Previous research 
also revealed an increase in total GAG content, especially DS, in mesangial 
cells collected from streptozotocin-induced diabetic rats16. This research 
showed the involvement of DS in renal disease as well as in regulating the 
ECM. However, the precise role of DS in the ECM of both the normal and 
the fi brotic kidney is not well understood. The absence of specifi c antibodies 
directed against specifi c domains in DS has hampered research on the 
role of DS in renal fi brosis. Some antibodies recognizing both DS and CS 
have been described17, and more recently two specifi c anti-DS antibodies 
(GD3A12 and LKN1) were reported by our lab18;19. The phage displayed-
derived anti-DS antibody LKN1 was shown to be especially reactive with 
4/2,4-di-O-sulfated DS, whereas antibody GD3A12 was especially reactive 
with IdoA-Gal-NAc4S18. Antibody LKN1 co-localized with type I collagen 
in various organs, including kidney, showing a typical fi brillar staining 
patt ern, whereas antibody GD3A12 showed only partial co-localization 
with type I collagen19.
 In this study we elucidate the expression of the diﬀ erent DS 
domains defi ned by antibodies LKN1 and GD3A12 using a panel of renal 
biopsies obtained from patients with acute interstitial, acute vascular and 
chronic renal allograft rejections, and from patients with focal segmental 
glomerulosclerosis (FSGS), membranous glomerulopathy (MGP) and 
systemic lupus erythematosus (SLE).
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Materials and Methods
Human kidney specimens
This study was approved by the Ethics Committ ee of the Radboud 
University Nijmegen Medical Centre and all participating patients gave 
informed consent. Human control kidneys (n = 4; average age: 50.7 ± 5.0 
years; range: 40–56 years) were obtained after surgical removal for renal 
cell carcinoma. Normal tissue was selected after macro- and microscopic 
evaluation. Needle renal biopsies were obtained from patients with focal 
segmental glomerulosclerosis (FSGS, n=11), membranous glomerulopathy 
(MGP, n=6), systemic lupus erythematosus (SLE, n=6) and renal allograft 
biopsies were obtained from patients with (according to Banﬀ  ‘97 
guidelines20) acute interstitial (n=6; Banﬀ ’97 class I, C4d negative), acute 
humoral/vascular (n=6; Banﬀ ’97 class II, C4d positive) and chronic (n=5; 
with slight to moderate fi brosis and tubular atrophy, class II) rejection. 
Four renal biopsies not showing any signs of rejection or other obvious 
pathology were used as control for the transplant rejection kidneys. 
Table 1. Clinical characteristics of transplanted patients with rejection.
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Immunofl uorescence staining
Indirect immunofl uorescence stainings were performed on 2 μm cryostat 
renal sections. Sections were fi xed in ice-cold acetone for 10 minutes and 
incubated with primary antibodies diluted in phosphate-buﬀ ered saline 
(PBS) containing 1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich 
Chemie BV, Zwijndrecht, The Netherlands) and 0.05% sodium azide 
(IF-buﬀ er) for 45 minutes at room temperature (RT).Primary antibodies 
included rabbit anti-bovine collagen type 1 (Millipore BV, Amsterdam, 
The Netherlands) and the anti-DS antibodies LKN119 and GD3A1218. 
Sections were rinsed with PBS and incubated with the appropriate Alexa 
488-conjugated IgG antibody (5 μg/ml, Molecular Probes, Leiden, The 
Netherlands) or anti-VSV-Cy3 (2 μg/ml, Sigma-Aldrich Chemie) in IF buﬀ er 
for 45 minutes at RT. Sections were rinsed with PBS and subsequently fi xed 
in 100% ethanol for 20 seconds, air-dried and embedded in Mowiol. The 
optimal dilution of antibodies LKN1, GD3A12, and anti-type I collagen 
used for staining were determined after titration on normal human kidney 
sections. The staining intensities of all antibodies were scored using 
arbitrary units (AU) on a scale between 0 and 10 (0 = no staining, 1 = 10% 
staining intensity, with a maximum score of 10 for 100% staining intensity) 
by two of the investigators on blinded sections.
Statistical analysis
Data are presented as mean ± standard deviation (s.d.) and, if not normally 
distributed, as median with interquartile ranges. For comparisons of 
diﬀ erent groups Mann-Whitney U tests were used. Statistical analysis was 
performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, 
CA, USA).
Table 2. Characteristics of patients with glomerular diseases.
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Results
Decreased expression of the4/2,4-di-O-sulfated DS domain defi ned by antibody 
LKN1 in the tubular interstitium in chronic allograft nephropathy (CAN)
The distribution of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS 
domains recognized by, respectively, the LKN1 and GD3A12 antibody 
was analysed in renal allograft rejection biopsies and controls (Fig.1 and 
2). Relevant clinical data of the patients are given in Table 1.
The 4/2,4-di-O-sulfated DS domain defi ned by LKN1 was expressed in the 
tubular interstitium, including the matrix surrounding Bowman’s capsule, 
with a distinct fi brillar expression patt ern (Fig. 1A). No expression inside 
the glomerulus was seen. Previously, we showed that this DS domain co-
localized with type I collagen19. 
Figure 1. Immunofl uorescence stainings of the 4/2,4-di-O-sulfated and IdoA-Gal-
NAc4S DS domains defi ned by the antibodies LKN1 (A-D) and GD3A12 (E-H) and 
type I collagen (I-L) in renal allograft rejection sections and controls. Representative 
photographs showing the expression of the 4/2,4-di-O-sulfated DS domain defi ned by 
LKN1 in the control human kidney (NHK) (A). Tubular interstitial expression of this4/2,4-
di-O-sulfated DS domain defi ned by LKN1 was increased in acute interstitial (B) and acute 
vascular (C) renal allograft rejections compared to CAN (D). Expression of the IdoA-Gal-
NAc4S DS domain recognized by GD3A12 was similar in the control human kidney and the 
three types of renal allograft rejection (E-H), while expression of type I collagen (coll I) was 
increased in CAN (J) compared to the control human kidney (I), and acute interstitial (K) and 
acute vascular renal allograft rejections (L).
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 In CAN, expression of the 4/2,4-di-O-sulfated DS domain 
recognized by antibody LKN1 was signifi cantly decreased in the tubular 
interstitium (Fig. 1D), whereas the expression in the acute interstitial (Fig. 
1B) and vascular renal allograft rejection (Fig. 1C) was similar to the control 
kidneys (Fig. 1A and 2A). The strongly decreased expression of the 4/2,4-di-
O-sulfated DS domain was accompanied by an increased expression of 
type I collagen in CAN (Fig. 1L and 2A). Type I collagen expression in 
acute interstitial (Fig. 1J) and acute vascular renal allograft rejection (Fig. 
1K) was similar to the control kidneys (Fig. 1I). Furthermore, glomerular 
staining of LKN1 was increased in CAN. Notably, similar increases also 
occurred in acute interstitial and vascular rejection (Fig. 2B).
 The expression patt ern of the IdoA-Gal-NAc4S DS domain 
recognized by the GD3A12 antibody in normal kidney was similar to the 
expression patt ern of the 4/2,4-di-O-sulfated DS domain defi ned by LKN1. 
Thus, also in this case no glomerular expression was observed (Fig. 1E). 
Furthermore, no diﬀ erences were observed between the expression of 
thisIdoA-Gal-NAc4SDS domain in the control group (Fig. 1E), and in the 
groups of patients with acute interstitial (Fig. 1F) or acute vascular renal 
allograft rejection (Fig. 1G) or CAN (Fig. 1H and 2A).
Increased expression of the 4/2,4-di-O-sulfated DS domain defi ned by antibody 
LKN1 in the tubular interstitium and glomeruli in human glomerular diseases
Since the specifi c DS domains were diﬀ erentially expressed in the diﬀ erent 
renal allograft rejection types, we also analyzed the expression of these 
diﬀ erent DS domains in three glomerular diseases FSGS, MGP and SLE. 
Relevant clinical data of these patients are given in Table 2. In all these 
glomerular diseases, the 4/2,4-di-O-sulfated DS domain recognized by 
the LKN1 antibody was expressed in the glomerulus in contrast to the 
controls (Fig. 3A and 4B). Furthermore, expression of this DS domain was 
signifi cantly increased in the tubular interstitium of patients with FSGS, 
MGP and SLE (Fig. 3A and 4B). In contrast to the 4/2,4-di-O-sulfated DS 
domain, the IdoA-Gal-NAc4S DS domain recognized by the antibody 
GD3A12 was not expressed in the glomeruli of patients with glomerular 
diseases (Fig. 3B and 4D). Furthermore, the expression of the IdoA-Gal-
NAc4S DS domain in the tubular compartment was similar in both normal 
and glomerular diseased kidneys (Fig. 3B and 4C). 
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Figure 2. Semi-quantitative analysis of the expression of type I collagen and the 
4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains defi ned by LKN1 and GD3A12 
of renal allograft rejection sections. Staining intensities of type I collagen and the DS 
domains defi ned by LKN1 and GD3A12 were scored semi-quantitatively and revealed a 
signifi cantly increased tubular interstitial expression of type I collagen and a decreased 
expression of the 4/2,4-di-O-sulfated DS domain recognized by LKN1 in CAN. Expression 
of the IdoA-Gal-NAc4S DS domain recognized by GD3A12 was similar in controls and the 
three renal allograft rejection types (A). Glomerular expression of the 4/2,4-di-O-sulfated DS 
domain defi ned recognized by LKN1 was increased in the acute interstitial, acute vascular 
and chronic renal allograft rejections compared to controls (NHK) (B). *P<0.05 vs control, 
^P<0.05.
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Figure 3. Expression of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains 
defi ned by LKN1 (A) and GD3A12 (B) in renal sections obtained from patients with 
glomerular diseases. Representative photographs showing the immunofl uorescence 
stainings of renal sections obtained from patients with focal segmental glomerulosclerosis 
(FSGS), membranous glomerulopathy (MGP) and systemic lupus erythematosus (SLE) or 
controls (NHK, normal human kidney) with the anti-DS antibodies LKN1 (A) and GD3A12 
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(B).
Figure 4. Semi-quantitative analysis of the expression the 4/2,4-di-O-sulfated 
and IdoA-Gal-NAc4S DS domains defi ned by LKN1 (A, B) and GD3A12 (C, D) in the 
interstitium (A, C) and glomeruli (B, D) of patients with FSGS, MGP and SLE. Staining 
intensities of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains defi ned by LKN1 
and GD3A12 respectively were scored semi-quantitatively and revealed a signifi cantly 
increased expression of the 4/2,4-di-O-sulfated DS domain in the interstitium (A) and 
glomeruli (B) of patients with glomerular diseases. Expression of the IdoA-Gal-NAc4S DS 
domain was similar in the interstitium (C) and glomeruli (D) of patients and controls (NHK, 
normal human kidney).
*P<0.05.
Discussion
This study shows the diﬀ erential expression of the specifi c 4/2,4-di-O-
sulfated and IdoA-Gal-NAc4S DS domains recognized by the anti-DS 
antibodies LKN1 and GD3A12, respectively, in the normal kidney and in 
renal pathology. Previous studies showed the expression of DS (and CS) in 
107
Diﬀ erential expression of specifi c dermatan sulfate domains 
5
the kidney, both in the glomerulus and in the tubular interstitium14;21;22. The 
4/2,4-di-O-sulfated DS domain is expressed in the tubular interstitial space, 
but not in the glomerulus in the normal situation, as is type I collagen19. 
Furthermore, the normal expression patt ern of the 4/2,4-di-O-sulfated DS 
domain resembles the expression of the two DSPGs, DCN and BGN, which 
are also expressed in the renal tubular interstitium with accumulations 
around the tubules, but no expression in the normal mesangial matrix23. 
For anti-DS antibody GD3A12 the normal expression patt ern, in the rat 
kidney, was previously shown to be associated with large blood vessels 
with a weaker staining present in the tubular interstitial space and near the 
Bowman’s capsule18. DS and DSPGs have been reported to be increased 
in several fi brotic renal diseases, including interstitial fi brosis, diabetic 
nephropathy, mesangial sclerosis and nephrosclerosis13;14. 
The expression of the 4/2,4-di-O-sulfated DS domain recognized by 
LKN1 was signifi cantly decreased in the tubular interstitium in biopsies of 
patients with CAN compared to biopsies of patients with acute rejections. 
In CAN there was an inverse correlation between the decreased expression 
of the 4/2,4-di-O-sulfated DS domain and the increased expression of type 
I collagen, suggesting a role for this specifi c DS domain recognized by 
antibody LKN1 in matrix remodelling and collagen formation in CAN. 
Importantly, glomerular LKN1 staining was not observed in controls, 
while patients with diﬀ erent forms of renal allograft rejections did have 
a glomerular LKN1 staining. In the biopsies of patients with glomerular 
disease, there was a similar increased glomerular expression of the 4/2,4-di-
O-sulfated DS defi ned by the antibody LKN1 as in the diﬀ erent forms of 
renal allograft rejections. Furthermore, the expression of the 4/2,4-di-O-
sulfated DS domain was signifi cantly increased in the tubular interstitium 
of patients with glomerular disease. In diabetic nephropathy it was shown 
that type I collagen depositions were not present in the glomerulus until 
advanced sclerosis occurred24. Since the specifi c 4/2,4-di-O-sulfated DS 
domain recognized by LNK1 is present at an earlier stage in the analyzed 
nephropathies, this anti-DS antibody might be useful in determining early 
changes in matrix deposition in the diseased kidney. It has been described 
that DS size increases in response to an insult, but returns to normal later 
on, thus regulating collagen fi bril formation25. The increase in DS staining 
observed in the tubular interstitium using our anti-DS antibody LKN1 
might refl ect the changes in DS size and sulfation needed for initial matrix 
modelling. However, whether type I collagen depositions are present in 
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the analyzed glomerular diseases and whether there is a correlation with 
the expression of the 4/2,4-di-O-sulfated DS domain recognized by LNK1 
requires additional research.
In contrast to the diﬀ erential expression of the 4/2,4-di-O-sulfated 
DS domain in the control, the diﬀ erent types of renal allograft rejections and 
the glomerular diseases, the expression of the IdoA-Gal-NAc4S DS domain 
recognized by the anti-DS antibody GD3A12 was not diﬀ erent for either 
the tubular interstitium or the glomerulus. Therefore, these data indicate 
a dynamic role for the specifi c DS domain recognized by the anti-DS 
antibody LKN1 in renal diseases. Although somewhat speculative, the main 
diﬀ erence between the domains recognized by LKN1 and GD3A12 may be 
2-O sulfation (4/2,4,-di O sulfation versus 4-O sulfation (=Ido-Gal-NAc4S)), 
indicating 2-O sulfation to be of major importance in nephropathies. 
Moreover, it has been shown that GAGs are involved during the early 
stages of chemokine att raction and static concentration gradient formation 
in renal allograft rejection, allowing an infl ammatory reaction to take place 
which can ultimately lead to transplant rejection26. An increase in CS was 
seen during acute renal allograft rejection26 and the biopsy specimens 
showed an enhanced capacity of binding a specifi c chemokine (CCL5). In a 
recent study by Rienstra et al.9 using an experimental renal transplantation 
model an up regulation of the CSPG versican in kidneys with increased 
interstitial fi brosis was shown. Since there was a decreased expression of 
the 4/2,4-di-O-sulfated DS domain in CAN and no change in the IdoA-Gal-
NAc4S DS domain, the expression ratio of these two domains might be 
useful in monitoring the progression of a possible chronic renal allograft 
rejection. This information may be useful for diagnostic purposes on renal 
biopsies. GAGs and DS can be readily detected in the urine, rendering the 
anti-DS antibody ratio LKN1:GD3A12 also useful for the (early) detection 
of renal disease. Furthermore, the described anti-DS antibodies might 
contribute to the development of glycomimetics, which may ultimately 
lead to a bett er treatment of selected renal nephropathies and even renal 
rejection.
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Abstract
The antibody phage display technique allows for the selection of antibodies 
against poorly immunogenic compounds, including glycosaminoglycans 
(GAGs), which are large negatively charged linear polysaccharides. The 
in vitro phage display technology has been successfully used to generate 
specifi c antibodies against GAGs. A large number of these antibodies react 
with basement membrane and matrix-associated GAG domains. However, 
antibodies reacting with GAGs at other locations (e.g. the luminal side 
of blood vessels) have not been selected, probably because of the low 
abundance of these GAGs in the preparations used for biopanning and/
or the vulnerability of the expressed structures (e.g. glycocalyx). To obtain 
antibodies to these endothelial GAGs we used a modifi cation of the phage 
display technique; the in vivo phage display. In this system, biopanning is 
performed in vivo, allowing antibody phage display libraries to interact 
with GAGs as they are present in tissues/organs. Using this approach, we 
selected and characterized 2 novel anti-heparan sulfate antibodies; JLiv2C2 
and JLiv18. 
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Introduction
Glycosaminoglycans (GAGs) are large linear, negatively charged 
polysaccharides that are distributed throughout the body. They play an 
important role in normal kidney function and in a myriad of biological 
processes like cell adhesion, migration and diﬀ erentiation. GAGs are 
present in basement membranes and at cell surfaces, and are build of 
up to 160 repeating disaccharide units. For heparan sulfate (HS), the 
dissacharide units are comprised of uronic acid and N-acetyl glucosamine 
residues. The uronic acid residue can be either a D-glucuronic acid or a 
L-iduronic acid with or without 2-O-sulfation. The glucosamine residue 
can be N-acetylated (NAc), N-sulfated (NS), or N-unsubstituted (NH3). In 
addition, the glucosamine residue can be 3-, and/or 6-O- sulfated. Most 
GAGs are att ached to a core protein forming a proteoglycan 1-3.
Due to the poor immunogenic nature of HS, standard methods to obtain 
antibodies , i.e. by immunization, are not very successful. Phage display 
technology was successfully adopted to generate specifi c antibodies against 
HS 4. So far, a large panel of  anti-GAG antibodies have been isolated and 
found to react mostly with basement membrane-bound HS domains 
in various organs 5;6. A number of these antibodies have been shown to 
be able to aﬀ ect physiological processes, like fi broblast growth factor 
(FGF)-2 induced cell proliferation, and anticoagulant activity of heparin 
5;7;8. However, antibodies reacting with GAGs at other locations (e.g. the 
luminal side of blood vessels) have not been selected, probably because 
of the low abundance of these GAGs in the preparations used and/or the 
vulnerability of the structures that they are present in (e.g. glycocalyx). 
To obtain antibodies to endothelial GAGs, we used a modifi cation of the 
phage display technique; the in vivo phage display. In the in vivo phage 
display technique a phage library is injected intravenously and after a 
period of circulation bound phages are eluted from the organs, and reused 
in further selection rounds. The in vivo phage display technique has been 
used by others, and antibodies have been selected and described 9;10. 
However, most of the in vivo panning data described involved random 
peptide expressing libraries, which identifi ed  for instance peptides that 
target selectively expressed receptors in mouse tumor vasculature 11. Two 
peptides have been selected against the rat melanoma proteoglycan core 
protein, and these peptides could specifi cally home to tumor vasculature 
in tumor-bearing mice 12. 
The in vivo phage display selection method has not been used to select 
antibodies to saccharides. To allow for the selection of specifi c anti-GAG 
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antibodies a phage display library enriched for GAG-binding antibodies 
was used. 
Selected antibodies may be useful in developing glycomimetica for targeted 
screening and/or therapeutic strategies based on selective expression of 
GAG domains.
Table 1.  Test molecules used for ELISA
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Methods 
Materials
All chemicals used were purchased from Merck (Darmstadt, Germany) 
unless stated otherwise. Bacterial medium (2× TY) was from Invitrogen 
(Carlsbad, CA). Isopropyl β-D-thiogalactopyranoside was from Sigma-
Aldrich Chemie (Zwijndrecht, The Netherlands). The protease inhibitor 
mixture was from Roche (Basel, Switz erland). Mowiol (4–88) was obtained 
from Calbiochem (La Jolla, CA, USA). Microlon 96-well microtiter plates 
were from Greiner (Frickenhausen, Germany). Protein A-Sepharose beads 
were from Amersham Biosciences. Heparin, heparan sulfate (HS) from 
porcine intestinal mucosa, HS from bovine kidney, chondroitinase ABC, 
and alkaline phosphatase-conjugated rabbit anti-goat IgG were purchased 
from Sigma (Zwijndrecht, The Netherlands). Recombinant heparinase III 
(from Flavobacterium heparinum) was a kind gift from IBEX Technologies 
(Montreal, QC, Canada). Goat anti-c-Myc tag polyclonal antibody A14 was 
from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-HS “stub” 
antibody (3G10) and anti- CS “stub” antibody (2B6) were from Seikagaku 
Kogyo Co. (Tokyo, Japan). Alexa 488-conjugated rabbit anti-mouse IgG, 
and Alexa 488-conjugated donkey anti-sheep were from Molecular Probes 
(Leiden, The Netherlands). Sheep anti-M13 polyclonal antibody was from 
Amersham Biosciences (Roosendaal, The Netherlands). All experiments 
were performed at ambient temperature (~22°C), unless stated otherwise. 
Growth and purifi cation of phages 
Growth and purifi cation were done as described 13, in short, the phage 
library was propagated as a phagemid in E. coli TG1 bacteria, and the 
phage-scFv particles were produced by the addition of VCS-M13 helper 
phage (Stratagene, La Jolla, CA). Phage-scFv were purifi ed from the culture 
supernatant by precipitation with 20% PEG-2.5 M NaCl, resuspended in 
a fi nal volume of 2 ml Dulbecco’s Modifi ed Eagle’s Medium (DMEM), 
and fi lter sterilized using a 0.45-μm fi lter (Schleicher & Schuell, Dassel, 
Germany).
Phage administration
Rats (approximately 8 weeks old) were sedated using narcovet (i.p.; 0.1 
mL/ 100 g. body weight) and were subsequently injected intravenously 
via the tail vein with approximately 1010 phages from an antibody phage 
display library, in which the CDR3 region of the heavy chain comprised 6 
amino acids in random sequence generally following a XBBXBX sequence 
(in which B is a basic amino acid and X can be any amino acid) in 200 μl 
DMEM.
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Five minutes after administration of the phages, rats were killed using 
an overdose of narcovet and subsequently perfused intracardially at 
physiological pressure with 5-10 ml DMEM to wash away the blood. After this, 
the kidneys were harvested, weighed and washed using DMEM containing 
protease inhibitors and cut into smaller pieces. These pieces were further 
grinded using a mortar and were resuspended in 2 mL of 2xTY medium 
containing 100 mM triethylamine. This solution was neutralized using 1 M 
Tris/HCl solution (pH 7.4), and E. coli TG1 bacteria were added (incubation 
at 37C; 30 min). 1.1012 VCS-M13 helper phages were added (incubation 
at 37C; 30 min). Bacteria were spun down and resuspended in 300 ml 
preheated 2xTY containing 100 g/ml ampicillin and incubated for 1 h at 37C 
while shaking. Kanamycin was added (25 g/ml) and incubation was for 
16 h at 30C while shaking. The phages were then grown and purifi ed as 
stated above. There were a total of four rounds of in vivo selection and 
amplifi cation.
After these rounds, bacteria were grown on TYE agar plates, and 50 single 
colonies were randomly picked after the third and fourth round of selection 
were grown in 2xTY medium. Periplasmic fractions were obtained as 
described before 13. 
Characterization of antibodies by Enzyme-Linked Immunosorbent Assay
Reactivity of the antibodies to various GAGs/molecules was evaluated 
by enzyme-linked immunosorbent assay (ELISA) as described 5;6. Briefl y, 
wells were coated o/n with the test molecules (see Table 1) by incubation 
with 100 μl of a 5 μg/ml solution in wells of a 96-well microtiter plate. 
The wells were rinsed with PBS containing 0.1% (v/v) Tween-20 (PBST), 
and blocked with 2% (w/v) bovine serum albumin (BSA) in PBS containing 
0.05% (v/v) Tween-20 for 90 min. Periplasmic fractions containing scFv 
antibodies were added, and allowed to bind for 60 min. Bound antibodies 
were detected with 1:500 diluted goat polyclonal anti-c-Myc IgG antibody 
A14 in PBS containing 2% (w/v) BSA and 0.05% (v/v) Tween-20, followed 
by incubation with 1:2,000 diluted alkaline phosphatase-conjugated rabbit 
anti-goat IgG in PBS containing 2% (w/v) BSA and 0.05% (v/v) Tween-20. 
The plates were rinsed six times with PBST following each incubation step. 
Enzyme activity was detected using 100 μl of 1 mg p-nitrophenyl phosphate/
ml 1 M diethanolamine/0.5 mM MgCl2, pH 9.8, as a substrate. Absorbance 
was read at 405 nm. All assays were performed at least three times and 
representative results are shown. As a control, wells were incubated with 
the irrelevant antibody MPB49 (CDR3 sequence WRNDRQ, VH3 family, 
germline segment DP38).
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Immunohistochemistry
Detection of bound phages was performed using polyclonal sheep anti-M13 
antibody. Kidneys of rats injected with the phage library were sliced 
into sections of 2 μm. After blocking non-specifi c binding sites with PBS 
containing 2% (w/v) BSA and 0.05% (v/v) Tween-20, sections were incubated 
with 1:500 diluted sheep anti-M13 antibody in PBS containing 2% (w/v) BSA 
and 0.05% (v/v) Tween-20 for 45 min. After washing with PBS, sections were 
incubated with 1:200 diluted donkey anti-sheep IgG Alexa 488 for 60 min. 
Sections were washed in PBS, fi xed in 96% ethanol, air dried, and embedded 
in Mowiol. As a control, kidney sections of non-injected rats were used.
To get more insight into the binding properties of the in vivo selected 
antibodies, sections of mice defi cient in enzymes essential for the 
epimerization, the 2-O- and the 6-O-sulfation of HS, were stained 
using the selected scFv antibodies. Hsepi+/- and Hsepi-/- (defi cient in the 
enzyme involved in the epimerization of glucuronic acid into iduronic 
acid) mouse embryos (17-18 d.p.c., obtained from Prof. Dr. U. Lindahl 
(Uppsala, Sweden)), Hs2st+/- and Hs2st-/- (defi cient in enzyme involved 
in the 2-O-sulfation of HS) mouse embryos (18.5 d.p.c., obtained from 
Dr. C. Merry (Manchester, UK)), and Hs6st+/-, and Hs6st-/- (defi cient in 
enzyme involved in the 6-O-sulfation of HS) mouse embryos (15.5 d.p.c., 
obtained from Prof. Dr. C. Habuchi (Nagakute, Japan)) were sliced into 4 
μm sections. In addition to sections from these mice, cryosections of rat 
kidney and liver were used to evaluate organ specifi city of the selected 
scFv antibodies. After blocking, sections were incubated with scFv 
antibodies in PBS containing 2% (w/v) BSA and 0.05% (v/v) Tween-20 for 
45 min. Bound antibodies were detected using 1:100 diluted rabbit anti-c-
Myc rabbit polyclonal antibody A-14 in PBS containing 2% (w/v) BSA and 
0.05% (v/v) Tween-20, and goat anti-rabbit IgG Alexa 488, each for 60 min. 
Cryosections were fi xed in 96% ethanol, air dried, and embedded in Mowiol. 
To evaluate the specifi city of the antibodies, cryosections from rat kidney  
were digested with the glycosidases heparinase III, (which digests HS) 
0.04 IU/ml in 50 mM NaAc/50 mM Ca(Ac)2, pH 7.0 or chondroitinase ABC 
(digests chondroitin sulfate (CS) and dermatan sulfate (DS)) 0.02 U/ml in 
25 mM Tris-HCl, pH 8.0, (o/n  at 37°C). As a control, cryosections were 
incubated in reaction buﬀ er without enzyme. After washing three times 
with PBS and blocking for 30 min with PBS containing 0.05% (v/v) Tween-20 
and 2% (w/v) BSA, cryosections were incubated with antibodies and 
processed for immunohistochemistry as described above. The eﬃ  ciency 
of heparinase III and chondroitinase ABC treatment was evaluated by 
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incubation of cryosections with antibodies against GAG-”stubs,” generated 
by the glycosidases. For HS stubs the antibody 3G10 was used. For CS stubs 
the antibody 2B6 was used. All tests were performed at least three times.
Figure 1. Immunostaining for M13 phage in rat kidney after injection of an antibody 
phage display library. Kidneys from PBS injected rats served as control and showed no 
staining using anti-M13 antibody (A). Staining for M13 in the kidneys of phage injected rats 
showed staining primarily present at the aﬀ erent and eﬀ erent arterioles (arrowheads) of the 
glomerulus and to a lesser extend in the glomerular capillary tuft (B), and in the peritubular 
capillaries (C, arrow). Bar, 50μm; *, Glomerulus. 
Results
Distribution of phage after injection
To check the distribution of the injected phages in the kidney, kidney 
cryosections from rats injected with the phage library were stained with 
an anti-M13 antibody directed against phage coat proteins. Cryosections 
of control kidneys were negative using the anti-M13 antibody (Fig. 1A). 
Kidney cryosections from phage-injected rats show primarily staining of 
the aﬀ erent and eﬀ erent arterioles of the glomerulus (Fig. 1B; arrowheads), 
but also in peritubular capillaries (arrow in Fig. 1C) and to a lesser extend 
in the glomerular capillary loop (Fig. 1B-C). 
Table 2. Characteristics of the in vivo phage display-derived anti-heparan sulfate 
antibodies
Given are the scFv antibody name, VH germ line gene family, DP gene segment number, and 
the amino acid and nucleotide sequence of the VH complementarity determining region 3 (VH 
CDR3). 
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Specifi city of the scFv antibodies
Based on the clonal phage-binding data, we selected two scFv 
antibodies (JLiv2C2 and JLiv18; Table 2) for further characterization. 
Immunofl uorescence staining studies were performed on normal rat kidney 
cryosections that were pre-treated with heparinase III or chondroitinase 
ABC . As a control, untreated rat kidney cryosections were used (Fig. 2A, 
D). Heparinase III-treatment resulted in loss of staining for both antibodies 
(Fig. 2B, E), whereas chondroitinase ABC treatment did not (Fig. 2C, F).
To further investigate which chemical groups are recognized by the 
antibodies, we determined their reactivity toward modifi ed K5 and heparin 
preparations (Table 1) in an ELISA (Fig. 3). K5 is a capsular polysaccharide 
from E. coli and is similar to the unmodifi ed HS precursor. The antibodies 
varied in their reactivity for diﬀ erent GAG species and for diﬀ erent modifi ed 
heparins and K5 (Fig. 3). They both reacted well with heparin and HS. No 
major reactivity was observed with CSA, DS, CSC and keratan sulfate (KS), 
nor with DNA, hyaluronic acid or the highly negatively charged dextran 
sulfate. The capsular polysaccharide K5, N-deacetylated and N-sulfated K5 
(NdAcNS K5), as well as completely desulfated and N-acetylated heparin 
(CdSNAc heparin), and completely desulfated and N-sulfated heparin 
(CdSNS heparin) were not recognized by the antibodies, indicating that 
they both need more than just N-acetylation or N-sulfation. In addition, 
the antibodies did not react with completely O-desulfated heparin (OdS 
heparin), indicating that the recognized domain comprises O-sulfates. 
Both antibodies reacted with the high as well as the low sulfated 
N-deacetylated, N- and O-sulfated K5 (NdAcNS/OS), and with the 
2-O-desulfated (2OdS heparin), and the 6-O-desulfated heparin (6OdS 
heparin), indicating that at least one sulfate position is necessary. 
The diﬀ erence between the two antibodies lies in the strong reactivity of 
JLiv18 with O-sulfated K5 (OS K5), and N-desulfated and N-acetylated 
heparin (NdSNAc heparin), whereas JLiv2C2 showed considerable less 
reactivity with these preparations. This suggests that antibody JLiv18 
primarily depends on O-sulfation in the recognized domain in order to be 
able to bind, whereas JLiv2C2 depends on both O-sulfated and N-sulfated 
groups for binding. In addition, epimerization seems not to be an essential 
modifi cation, since some K5-derived preparations (all non-epimerized) 
reacted well with the antibodies.
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Figure 2. Immunostaining of untreated, heparinase III (hepIII)- or chondroitinase ABC 
(chonABC)-treated rat kidney cryosections with in vivo selected phage display-derived 
anti-glycosaminoglycan (anti-GAG) antibodies JLiv18 and JLiv2C2. In untreated (A, D) 
and chonABC treated (C, F) rat kidney cryosections the epitopes recognized by the antibodies 
JLiv18 (A, C) and JLiv2C2 (D, F) are present in the rat kidney. In the hepIII-treated rat kidney 
cryosections the epitope for JLiv18 (B) as well as for JLiv2C2 (E) is removed by the enzyme 
treatment. Bar, 50μm.
To further characterize the structural features of the HSdomains recognized 
by the antibodies, embryos defi cient in the HS-modifying enzymes 
2-O-sulfotransferase, which transfers sulfate to the C-2 of uronic acid; 
these embryos lack HS 2-O-sulfation14 and 6-O-sulfotransferase, which 
transfers sulfate to the C-6 position of the amino sugars, were stained. The 
latt er embryos only lack some 6-O-sulfation since there are 2 additional 
isoenzymes of 6-O sulfotransferase which are not  defi cient in these embryo’s. 
Also embryo’s defi cient in  C5-epimerase, which converts glucuronic acid 
to iduronic acid, and therefore lack epimerized HS domains15 were stained. 
None of the HS-modifying enzyme-defi cient embryos showed a marked 
decline in staining (data not shown), supporting our fi ndings using the 
ELISA approach (Fig. 3). 
Organ distribution of the selected scFv antibodies
The reactivity of the two HS domain-recognizing antibodies in two diﬀ erent 
organs (kidney and liver) was evaluated using immunohistochemistry and 
is depicted in fi gure 4. These organs were chosen because of the presence 
of an extensive vasculature. For both antibodies, the staining patt erns 
in the kidney were similar. The antibodies primarily reacted with the 
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peritubular capillaries, glomerular capillary loops and the mesangium. 
Antibody JLiv18 stained the glomerular capillary wall, but more intensely 
the mesangium (Fig. 4A). Antibody JLiv2C2 also stained the peritubular 
capillaries, but showed a uniform staining of the glomerular capillary wall 
and the mesangium (Fig. 4C). Both antibodies did stain capillaries within 
the liver, but less intense than seen in the kidney sections (Fig. 4B and D).
Figure 3. Reactivity of in vivo phage display-derived anti-heparan sulfate (HS) 
antibodies JLiv18 and JLiv2C2 with various immobilized GAGs/molecules in ELISA. 
Given is the reactivity of JLiv18 and JLiv2C2 with the test molecules relative to unmodifi ed 
heparin (set at 100%) Values are given as mean ± SD (n=4). O-sulfate groups are essential 
for the binding of antibody JLiv18. Both N- and O-sulfate groups are essential for antibody 
JLiv2C2 binding. The antibodies showed no/weak reaction with DS, CSA, CSC, DNA, 
hyaluronic acid, dextran sulfate and KS. 
K5: K5 polysaccharide (the non-sulfated non-epimerized precursor polysaccharide of HS/
heparin); NdAcNS K5: N-deacetylated and N-sulfated K5; OS K5: O-sulfated K5; NdAcNS/
OS K5: N-deacetylated and N- and O-sulfated K5; CdSNAc heparin: completely desulfated 
and N-acetylated heparin; CdSNS heparin: completely desulfated and N-sulfated heparin; 
NdSNAc heparin: N-desulfated and N-acetylated heparin; 2OdS heparin: 2-O-desulfated 
heparin; 6OdS heparin: 6-O-desulfated heparin; OdS heparin: O-desulfated heparin; DS, 
dermatan sulfate; CSA,-C, chondroitin sulfate A,-C; DNA; Hyaluronic acid; dextran sulfate; 
KS: keratan sulfate.
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Figure 4. Immunostaining for heparan sulfate (HS) domains in rat kidney and liver 
cryosections using in vivo phage display-derived anti-glycosaminoglycan (anti-GAG) 
antibodies JLiv18 and JLiv2C2. Staining for the HS domains in kidney showed strong 
reaction for JLiv18 (A) and JLiv2C2 (C), whereas staining for liver HS domains is less intense 
using JLiv18 (B), and JLiv2C2 (D). Bar, 50μm
To analyse whether the antibodies recognized luminal HS domains, 
a double staining with anti-laminin (present in the basal lamina) was 
performed using human kidney sections. In fi gure 5A JLiv18 staining is 
shown, resembling the staining in the rat. In fi gure 5-A1, the boxed area 
drawn in panel A is shown in greater detail and suggests luminal staining 
of the capillary wall (arrows) and in addition the mesangium. In fi gure 5B 
JLiv2C2 staining in human kidney is shown, which is also resembling the 
staining in rat kidneys. In fi gure 5-B1 the boxed area in panel B is shown in 
greater detail, showing the more evenly distribution of this antibody along 
the GBM, and also here there is the suggestion of luminal capillary wall 
staining (arrows). 
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Figure 5. Immuno double-staining for heparan sulfate (HS) domains and laminin 
in normal human kidney cryosections using in vivo phage display-derived anti-
glycosaminoglycan (anti-GAG) antibodies JLiv18 and JLiv2C2. Staining for the HS 
domains in kidney using JLiv18 (A) and JLiv2C2 (B) is shown in green and laminin in red. In 
the right panel an enlargement of the boxed areas of the left panel is shown (A1: JLiv18 and 
B1: JLiv2C2). In A1 it is shown that JLiv18 stains predominantly the mesangial area, but also 
some luminal staining is visible (arrow in A1). In B1 JLiv2C2 appears to be expressed at the 
endothelial side of the GBM (arrows in B1), as well as in the GBM itself. 
Bar A-B, 50μm; A1-B1, 10μm.
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Discussion
This is the fi rst time that the in vivo phage display technique has been 
successfully used to obtain anti-GAG antibodies. We selected two distinct 
antibodies as indicated by their unique VH CDR3 sequences and their 
diﬀ erent binding characteristics using an ELISA. Both antibodies showed 
strong staining for renal HS-associated domains.
Previous studies validated the in vivo phage display technique, and selected 
specifi c antibodies and peptides directed against vascular cell surface 
proteins and receptors. Furthermore, it has been possible to direct binding 
of these antibodies to selective vascular beds 16 and to tumor blood vessels 
11 in vivo. 
HS binds and modulates a vast amount of proteins, like the growth factors 
FGF-2 and vascular endothelial growth factor, but also chemokines such 
as CXC and CC 2;17. Many of these “heparin binding” proteins play an 
important role in the kidney, both in health and disease. This indicates the 
importance of HS within the kidney, and the need for specifi c antibodies to 
further investigate these intriguing polysaccharides.
The antibodies both recognize diﬀ erent HS domains, as primarily 
indicated by the ELISA results. Antibody JLiv18 only depends primarily on 
O-sulfation present, whereas antibody JLiv2C2 depends on the presence of 
both O-sulfation and N-sulfation. 
Unfortunately, we cannot directly check for the binding of the antibody to 
3-O-sulfated domains due to the lack of available tools. The high sulfated 
NdAcNS/OS K5 does have 3-O-sulfation, but not at its physiological 
position. 
The absence of 6-O-sulfation in the 6OdS heparin is not complete, there 
still remains 23% 6-O-sulfation. We do not see any signifi cant increase or 
decline in reaction towards this 6OdS heparin sample for both antibodies, 
suggesting high 6-O-sulfation is not of major importance for the binding of 
either of the two antibodies. 
Antibody JLiv18 shows a remarkable resemblance in VH CDR3 amino 
acid sequence with antibody HS4C3, which we previously selected and 
described 8;18. There is just one amino acid diﬀ erence between the two 
VH CDR3 sequences, the sequence of JLiv18 is GRRAKD, and that of 
HS4C3 is GRRLKD. HS4C3 recognizes 3-O-sulfates and binds to the anti-
thrombin binding pentasaccharide sequence, thereby neutralizing the 
blood anticoagulant activity of heparin 18. The other antibody, JLiv2C2, 
also resembles the HS4C3 antibody, but primarily in its staining patt ern 
in the kidney. Further examination and comparison of these three anti-
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HS antibodies would be very interesting and could provide further 
understanding of the tight regulation of HS domains in the body. 
The binding of the two selected scFv antibodies is not exclusively to the 
luminal side of blood vessels and most of their binding seems to be non-
luminal. However, staining suggest that part of the domains recognized 
are located at the luminal side of the basement membrane. An antibody 
which exclusively reacts with a HS species present only at the luminal 
site of the endothelium has not been obtained so far. In this respect, an 
alternative way of in vivo panning as we performed now  may be possible, 
by allowing the phages to bind to their specifi c GAG domains in vivo and 
then elute them after enzymatic cleavage of the GAGs using heparinase 
or chondroitinase instead of mincing the tissue as we did now. Another 
possibility is in vitro panning on cultured glomerular endothelial cells.
The selection of anti-GAG antibodies using the in vivo phage display 
technique may yield further insight in the cell biological relevance of GAG 
domains present on the vascular endothelial cells in diﬀ erent organs. New 
insights in the structure and function of endothelial HS may lead to the 
development of glycomimetica that can be used in the treatment of a wide 
array of diseases. 
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Glycosaminoglycans (GAGs) are major components of normal renal cells 
and matrices. The majority of GAGs are covalently bound to a core protein 
to form proteoglycans. Although the core protein is undoubtedly important 
in a large number of physiological and pathological processes, the GAG 
side chain is also involved in a myriad of processes. Antibodies directed 
against specifi c GAG domains have become available in recent years and 
are powerful tools to study GAGs. Up to now the research was primarily 
focused on heparan sulfate (HS), with litt le att ention to chondroitin sulfate 
(CS) and dermatan sulfate (DS). This was mainly due to the lack of proper 
tools, i.e. specifi c antibodies directed against specifi c domains in DS. 
The overall aim of this thesis was to evaluate the role of GAGs and 
in particular specifi c GAG domains in renal (patho)physiology, with a 
focus on DS by application of phage display techniques generating specifi c 
anti-DS antibodies. 
The distribution and relevance of proteoglycans and GAGs, mainly HS 
and CS, in the normal kidney and during fi brosis (both glomerulosclerosis 
and tubulointerstitial fi brosis) are described in Chapter 1. GAGs have been 
implicated in matrix production and are involved in sclerosis and fi brosis. 
In this respect CS and DS are of special interest since these are located in 
the extracellular matrix and are linked to the binding and modulation of 
pro-fi brotic growth factors such as transforming growth factor (TGF)-beta. 
The technology to obtain specifi c antibodies to GAGs, the phage display 
technology, is also introduced. The phage display technology allows for the 
clonal selection of scFv antibodies against poor immunogenic molecules, 
like GAGs, including DS. In Chapter 2 the phage display technique, which 
is used to generate a panel of anti-GAG antibodies is further detailed. 
The selection procedure and the characterization/application of GAG 
antibodies is explained. Additional techniques to characterize the epitope 
recognized by the selected antibodies are discussed, including enzyme-
linked immunosorbent assay (ELISA) and immunohistochemistry. In 
Chapter 3 we describe the GAG expression patt ern present in normal rat 
and human kidneys. A panel of several anti-HS and anti-CS antibodies was 
applied. Human kidney sections were stained with the panel of anti-HS 
and anti-CS antibodies. Co-stainings with antibodies specifi c for diﬀ erent 
nephron segments were used to localize the domains recognized by the 
selected panel of anti-GAG antibodies. The CS domain recognized by the 
antibody IO3H10 was mainly localized in the tubular interstitium, whereas 
the majority of HS domains was located in the basement membranes/cell 
surfaces. Partial overlap in staining patt erns of the anti-GAG antibodies 
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with diﬀ erent proteoglycan core proteins was observed. The two 
antibodies HS4C3 and RB4Ea12, which recognize a highly sulfated HS 
domain and a low sulfated HS domain, respectively, were studied using 
mesangial cell cultures. It was shown that addition of FGF-2 was able to 
induce cellular proliferation, which was blocked by the addition of the 
anti-HS antibody HS4C3. This fi nding indicates that the highly sulfated 
HS domain recognized by antibody HS4C3 is involved in FGF-2-induced 
signaling in mesangial cells. Our fi ndings also indicate that our anti-
GAG antibodies can be used for functional testing, thus allowing for the 
investigation of the role of the recognized GAG domain. A next step was 
the selection and characterization of antibodies directed against interstitial 
DS. DS is the epimerized form of CS, which can be found in the interstitial 
tubular compartment of the kidney. Since there were no specifi c anti-DS 
antibodies available, in Chapter 4 a modifi ed phage display procedure 
using synthetic medium was used to select new anti-DS antibodies, which 
yielded an antibody called LKN1. LKN1 was DS specifi c and further 
analyses using an ELISA approach with diﬀ erent well-characterized DS 
molecules revealed its specifi city for a DS domain containing 4/2,4-di-O-
sulfation. In addition, immunohistochemistry was performed using tissues 
known to contain very high amounts of specifi cally sulfated DS, including 
4/2,4-di-O-sulfated DS from Styela plicata and 2,6-di-O-sulfated DS from 
Ascidia nigra. Using both immunohistochemistry and immuno-electron 
microscopy the DS epitope was found to co-localize with type I collagen 
fi brils. LKN1 appeared to be a unique anti-DS antibody directed against a 
specifi c DS domain, which was further evaluated in Chapter 5. The anti-DS 
LKN1 antibody, which is especially reactive with a 4/2,4-di-O-sulfated DS 
domain, together with the anti-DS antibody, GD3A12, which recognizes a 
IdoA-Gal-NAc4S-containing DS domain, were used to study the expression 
of their respective DS domains in the normal kidney. The DS domains 
were also studied in diﬀ erent types of renal transplant rejection, i.e. acute 
interstitial, acute vascular and chronic rejection, and in renal biopsies from 
patients with focal segmental glomerulosclerosis (FSGS), membranous 
glomerulonephritis (MGN) and systemic lupus erythematosus (SLE). 
The DS domains defi ned by LKN1 and GD3A12 were both present in the 
interstitial area, but not inside the glomerulus in the normal kidney. The 
expression of the 4/2,4-di-O-sulfated-containing DS domain defi ned by 
LKN1 was decreased in the interstitium of renal allografts with chronic 
rejection, which was accompanied with an increased expression of type 
I collagen. In contrast, in the interstitium of kidneys with FSGS, MGN 
and SLE there was an increased expression of the DS domain defi ned by 
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LKN1. Moreover, the expression of the DS domain defi ned by LKN1 was 
increased in the glomeruli in all diseased kidneys. For the DS domain 
defi ned by GD3A12 there was no diﬀ erence in expression in the interstitium 
and the glomerulus between the normal and the kidneys with transplant 
rejection, and between the normal kidneys and renal biopsies with FSGS, 
MGN and SLE. These data suggest a role for the increased expression of 
the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 in renal 
diseases with early fi brosis, but not of the IdoA-Gal-NAc4S DS domain 
recognized by GD3A12. A variation of the phage display technique was 
described in Chapter 6, i.e. the in vivo phage display technique. Here, we 
injected a phage display library enriched for GAG binding scFv-expressing 
phages into living rats. Selection of kidney reactive anti-GAG antibodies 
was performed by harvesting kidney-bound phages and using them in 
subsequent rounds of panning and amplifi cation. Using the in vivo panning 
approach, two distinct anti-GAG antibodies were selected that showed a 
good staining in the normal kidney. Further characterization of the two 
selected anti-GAG antibodies showed a very high similarity of one of them 
(JLiv18) at the base pair level with the known antibody HS4C3 (only one 
amino acid diﬀ erence). Using an ELISA approach with well characterized 
GAGs, there was a clear diﬀ erence between the known antibody HS4C3 
and the two in vivo selected anti-GAG antibodies, but also between the 
two in vivo selected anti-GAG antibodies. This new in vivo phage display 
approach might be used for targeting blood facing GAGs and provide a 
quick access to them. 
Future perspectives
 In this thesis the phage display technique was used to generate 
antibodies directed against specifi c GAG domains and the role of these 
GAG domains in normal renal (patho)physiology was investigated. There 
are indications that the 4/2,4-di-O-sulfated DS domain recognized by 
antibody LKN1 plays an important role in early fi brotic renal diseases. To 
study the structure-function relationship in renal diseases of the DS domain 
defi ned by LKN1, and of other GAG domains as well, GAGs should be 
extracted from renal tissue of a range of fi brotic renal diseases as well as 
from diﬀ erent transplant rejection kidneys and control kidneys. Separate 
isolation of GAGs from the glomerular compartment and the tubular 
compartment is recommended, since for example the DS domain defi ned 
by LKN1 is only expressed in the diseased glomeruli and not in the normal 
glomeruli. The extracted GAGs should be analyzed for their chemical 
make-up using disaccharide analysis by mass spectrometry. For this 
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GAGs are fl uorescently labeled, followed by fractionating using reverse-
phase ultra-performance liquid chromatography and then analyzed by 
electrospray ionization mass spectrometry. To get more homogenous GAG 
preparations, partially digested GAGs derived from the kidney may be 
aﬃ  nity purifi ed using for example the anti-DS antibody LKN1, followed 
by structural analysis. Furthermore, the presence of specifi c DS domains, 
but also HS domains, can be measured in the blood and urine over time in 
animal models of renal fi brotic disease. In addition, a patient study can be 
designed using the urine and blood of kidney transplant patients over time 
and correlating the presence of specifi c DS/HS domains with renal biopsy 
data and other clinical parameters such as urinary albumin and glomerular 
fi ltration rate. If clinical parameters could be correlated to the presence of 
specifi c DS/HS domains in the urine and/or blood, this might be used as 
non-invasive diagnostic and prognostic marker.
 To gain more insight into the fundamental role of DS and GAGs 
in the development of inherited renal disease, animals should be sampled 
starting in utero with follow up at diﬀ erent time points until there is 
prominent renal disease. Comparing the expression of specifi c DS and/
or GAG domains during normal renal development versus inherited renal 
diseases, may provide a basis for the identifi cation of critical processes 
in the development of the kidney in general and of inherited renal 
diseases in particular that are related to specifi c DS and/or HS domains. 
Ultimately, this kind of studies could lead to the rational development of 
defi ned DS or HS-based therapeutics. The potential role of such DS or HS-
based glycomimetics in treating renal disease can be evaluated in in vivo 
experimental models of renal disease. 
Recently, a novel hypothesis has been put forward suggesting a key role for 
DS in autoimmunity1. This adds to the already highly diverse roles of DS in 
health and disease. The tools generated in this thesis may be instrumental 
in further dissecting the pathophysiological consequences of (altered) DS 
domain structures.
1.  Rho JH, Zhang W, Murali M, Roehrl MH, Wang JY: Human proteins with aﬃ  nity 
for dermatan sulfate have the propensity to become autoantigens. Am J Pathol. 
178:2177-2190, 2011
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Glycosaminoglycanen (GAG’s) zijn belangrijke componenten van 
normale niercellen en matrices. De meerderheid van de GAG’s zijn 
covalent gebonden aan een eiwitketen en vormen samen proteoglycanen. 
Hoewel de eiwitketen belangrijk is in een groot aantal fysiologische en 
pathologische processen, is de GAG  zijketen ook betrokken bij een groot 
aantal processen. Antilichamen gericht tegen specifi eke GAG  domeinen 
zijn in de afgelopen jaren beschikbaar gekomen en zijn krachtige tools om 
GAG’s te bestuderen. Tot nu toe was het onderzoek vooral gericht op de 
GAG heparansulfaat (HS), met weinig aandacht voor de GAG’s van het 
type chondroïtinesulfaat (CS) en dermataansulfaat (DS). Dit was vooral 
te wijten aan het ontbreken van de juiste tools, dat wil zeggen specifi eke 
antilichamen gericht tegen specifi eke domeinen van deze GAG’s.
Het algemene doel van dit proefschrift was het evalueren van de rol van 
GAG’s en in het bijzonder van specifi eke GAG  domeinen in renale (patho)
fysiologie, met een focus op DS door de toepassing van specifi eke anti-
DS antilichamen gegenereerd met behulp van phage display technieken.
Het voorkomen en de relevantie van proteoglycanen en GAG’s, voornamelijk 
HS en CS, in de normale nier en bij fi brose (zowel glomerulosclerose 
en tubulointerstitiele fi brose) wordt beschreven in Hoofdstuk 1. GAG’s 
zijn betrokken bij matrixproductie en bij sclerose en fi brose. CS en DS 
zijn in dit verband van bijzonder belang aangezien ze aanwezig zijn in 
de extracellulaire matrix en betrokken zijn bij de binding en modulatie 
van pro-fi brotische groeifactoren zoals transformerende groeifactor 
(TGF)-beta. De technologie om specifi eke antilichamen te verkrijgen 
tegen GAG’s, de phage display technologie, wordt ook in dit hoofdstuk 
geïntroduceerd. De phage display technologie maakt de selectie mogelijk 
van klonale scFv antilichamen tegen slecht immunogene moleculen zoals 
GAG’s, inclusief DS. In Hoofdstuk 2 wordt de phage display techniek, die 
is gebruikt om een  panel van anti-GAG-antilichamen te genereren, nader 
uitgewerkt. De selectieprocedure en de karakterisering / toepassing van 
anti-GAG antilichamen wordt nader toegelicht. Additionele technieken 
voor het verder karakteriseren van het epitoop die wordt herkend door de 
geselecteerde antilichamen worden besproken, waaronder de enzym-linked 
immunosorbent assay (ELISA) en de immunohistochemie. In Hoofdstuk 
3 wordt het GAG-expressiepatroon in de normale rat en humane nier 
beschreven. Een panel van verscheidene anti-HS en anti-CS antilichamen 
werd toegepast. Humane niercoupes werden gekleurd met dit panel. Co-
lokalisatie met nefronsegment-specifi eke antilichamen werd gebruikt 
voor de precieze lokalisatie van de domeinen die herkend worden door 
het geselecteerde panel van anti-GAG antilichamen. Het CS domein dat 
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werd herkend door antilichaam IO3H10 was voornamelijk gelokaliseerd 
in het tubulaire interstitium, terwijl de overwegende meerderheid van HS-
domeinen was gesitueerd in de basaalmembranen / celoppervlak. Er was 
een gedeeltelijke overlap in expressie van de anti-GAG antilichamen met 
de verschillende proteoglycaaneiwitketens. De twee antilichamen HS4C3 
en RB4Ea12, die respectievelijk een hoog gesulfateerd HS domein en een 
laag gesulfateerd HS domein herkennen, werden bestudeerd met behulp 
van mesangiale celculturen. Er werd aangetoond dat de toevoeging van 
FGF-2 deze cellen aanzett e tot proliferatie,  die vervolgens geblokkeerd 
kon worden door de toevoeging van het anti-HS antilichaam HS4C3. Deze 
bevinding geeft aan dat het hoog gesulfateerde HS-domein herkend door 
antilichaam HS4C3 betrokken is bij de FGF-2-geïnduceerde signalering 
in mesangiale cellen. Deze bevindingen geven tevens aan dat  onze anti-
GAG-antilichamen ook gebruikt kunnen worden voor functionele testen, 
wat het mogelijk maakt  de rol van GAG domeinen te onderzoeken. 
Een volgende stap was de selectie en karakterisering van antilichamen 
gericht tegen interstitiële DS. DS is de geëpimeriseerde vorm van CS en is 
aanwezig in de tubulaire interstitiële ruimte van de nieren. Aangezien er 
geen specifi eke anti-DS antilichamen beschikbaar zijn werd in Hoofdstuk 
4 een gemodifi ceerde phage display procedure, gebruik makende van 
synthetisch medium, ingezet om nieuwe anti-DS antilichamen te selecteren. 
Dit leverde een antilichaam genaamd LKN1 op. LKN1 was DS specifi ek 
en verdere analyse met behulp van een ELISA met verschillende goed 
gekarakteriseerde DS moleculen leverde aanwijzingen voor de specifi citeit 
op voor een DS domein met 4/2 ,4-di-O-sulfatering. Bovendien werd 
immunohistochemie toegepast op weefsels waarvan het bekend is dat ze 
zeer grote hoeveelheden specifi ek gesulfateerde DS bevatt en, inclusief 4/2 
,4-di-O-gesulfateerde DS van Styela plicata en 2,6-di-O-gesulfateerde DS 
van Ascidia nigra. Met behulp van zowel immunohistochemie en immuno-
elektronenmicroscopie bleek het DS epitoop te co-lokaliseren met type 
I collageenfi brillen. LKN1 bleek een uniek anti-DS antilichaam te zijn 
gericht tegen een specifi ek DS-domein, hetgeen verder werd onderzocht 
in Hoofdstuk 5. Het LKN1 antilichaam, dat met name reactief is met een 
4/2 ,4-di-O-gesulfateerde DS domein,  samen met het anti-DS antilichaam 
GD3A12, dat reactief is met een IdoA-Gal-NAc4S bevatt end DS domein, 
werd gebruikt om de expressie van DS-domeinen in de normale nier te 
bestuderen. De DS-domeinen werden ook bestudeerd in verschillende 
typen van nier-transplantaat afstotingen, te weten acute interstitiële, 
acute vasculaire en chronische afstoting en in renale biopten van 
patiënten met focale segmentale glomerulosclerose (FSGS), membraneuze 
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glomerulonefritis (MGN) en systemische lupus erythematosus (SLE). De 
DS domeinen gedefi nieerd door LKN1 en GD3A12 waren beide aanwezig 
in de interstitiële ruimte, maar niet in de glomerulus van de normale nier. 
De expressie van het 4/2,4-di-O-gesulfateerde DS domein was verminderd 
aanwezig in het interstitium van niertransplantaten met chronische 
afstoting, en ging gepaard met een verhoogde expressie van type I collageen. 
In het interstitium van de nieren met FSGS, MGN en SLE daarentegen, 
was er juist een verhoogde expressie van het DS-domein gedefi nieerd door 
LKN1. Bovendien was de expressie van dit DS-domein verhoogd in de 
glomeruli van alle aangedane nieren. Voor het DS-domein gedefi nieerd 
door GD3A12 werden geen verschillen waargenomen in expressie in het 
interstitium en de glomerulus bij de normale en aangedane nieren. Deze 
gegevens suggereren een rol van het 4/2 ,4-di-O-gesulfateerde DS-domein 
bij nierziekten met beginnende fi brose, maar niet voor het IdoA-Gal-
NAc4S DS-domein. Een variatie op de phage display techniek - in vivo 
phage display - werd gebruikt in Hoofdstuk 6. Hier hebben we een phage 
display bibliotheek verrijkt voor fagen met GAG bindende antilichamen 
en deze, geïnjecteerd bij ratt en. De selectieprocedure voor  nier-reactieve 
anti-GAG antilichamen bestond uit het oogsten van nier-gebonden fagen 
en het gebruik ervan in de daaropvolgende ronden van biopannen en 
opwerking. Deze in vivo panning benadering leverde twee verschillende 
anti-GAG antilichamen op die een goede kleuring in de normale nier 
lieten zien. Verdere karakterisatie van deze antilichamen toonde een grote 
overeenkomst voor een van hen (JLiv18) op aminozuurvolgordeniveau 
met goed beschreven antilichaam HS4C3 (slechts een aminozuur verschil). 
Een ELISA-aanpak met goed gekarakteriseerde GAG’s liet een duidelijk 
verschil tussen het antilichaam HS4C3 en de twee geselecteerde in vivo anti-
GAG-antistoﬀ en zien, maar ook tussen de twee geselecteerde antilichamen 
onderling. Deze nieuwe in-vivo-phage display aanpak zou gebruikt 
kunnen worden voor het selecteren van antilichamen gericht tegen GAG’s 
die voorkomen in bloedvaten. 
Toekomstvisie
In dit proefschrift werd de phage display techniek gebruikt om 
antilichamen gericht tegen specifi eke GAG-domeinen te genereren en 
werd de rol van deze GAG-domeinen in  nier (patho)fysiologie onderzocht. 
Er zijn aanwijzingen dat het door antilichaam LKN1 herkende 4/2 ,4-di-
O-gesulfateerde DS domein een belangrijke rol speelt bij beginnende 
fi brotische nierziekten. Om de structuur-functie relatie bij nierziekten van 
het DS-domein en van andere GAG domeinen te bestuderen moeten GAG’s 
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worden gewonnen uit nierweefsel van diverse door fi brose gekenmerkte 
nierziekten en uit verschillende afgestoten transplantaat nieren en controle 
nieren. Afzonderlijke isolatie van de GAG’s uit de glomerulaire en tubulaire 
compartiment wordt aanbevolen aangezien bijvoorbeeld het door LKN1 
gedefi nieerde DS-domein alleen tot expressie komt in de aangedane 
glomeruli en niet in de normale glomeruli. De geëxtraheerde GAG’s zouden 
dan geanalyseerd kunnen worden op hun chemische samenstelling door 
middel van disaccharideanalyse en massaspectrometrie. Hierbij worden 
GAGs fl uorescerend gelabeld, gevolgd door fractioneren met behulp van 
bijvoorbeeld reverse-phase ultra-performance vloeistofchromatography 
en dan kunnen ze worden geanalyseerd door electrospray ionisatie 
massaspectrometrie. Om meer homogene GAG preparaten te krijgen 
kunnen gedeeltelijk gedigesteerde nier GAG’s gezuiverd worden met 
behulp van bijvoorbeeld de aﬃ  niteit voor anti-DS antilichaam LKN1, 
gevolgd door structurele analyse. Bovendien kan de aanwezigheid van 
specifi eke DS, maar ook HS, domeinen in de tijd gemeten worden in bloed 
en urine van diermodellen met renale (fi brotische) ziekte. Verder kan er 
een patiëntonderzoek worden ontworpen waarbij de urine en het bloed 
van niertransplantatiepatiënten in de tijd worden verzameld en waarbij 
de aanwezigheid van specifi eke DS / HS domeinen wordt gerelateerd 
aan nierbiopsie gegevens en klinische parameters zoals de glomerulaire 
fi ltratiesnelheid. Wanneer de klinische parameters kunnen worden 
gecorreleerd aan de aanwezigheid van specifi eke DS / HS-domeinen in 
de urine en / of het bloed, kan dit worden toegepast als niet-invasieve 
diagnose- en prognosemarker.
Om meer inzicht te krijgen in de fundamentele rol van DS en GAG’s in 
de ontwikkeling van erfelijke nierziekten, zouden er bij diermodellen al 
in de embryonale fase gesampeld moeten worden met een follow-up op 
verschillende tijdstippen tot er een overte  nierziekte is. Vergelijking van 
de expressie van specifi eke DS en / of GAG domeinen tijdens de normale 
nierontwikkeling versus de ontwikkeling tijdens erfelijke nierziekten, 
kan als basis dienen voor de identifi catie van de essentiële processen 
die verband houden met specifi eke DS en / of HS domeinen tijdens de 
ontwikkeling van de nier in het algemeen en van erfelijke nierziekten in het 
bijzonder. Uiteindelijk zou dit soort studies kunnen leiden tot de rationele 
ontwikkeling van goed gedefi nieerde op DS of HS-gebaseerde therapeutica 
(glycomimetica), welke geëvalueerd kunnen worden in in vivo modellen 
van de nierziekte.
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Samenvatt ing en toekomstvisie
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Onlangs is er een nieuwe hypothese naar voren gebracht die een belangrijke 
rol voor DS in auto-immuniteit suggereert1. Dit draagt bij aan de toch al 
zeer diverse rol van de DS bij gezondheid en ziekte. De tools die in dit 
proefschrift ontwikkeld zijn  kunnen een bijdrage leveren bij het verder in 
kaart brengen van de pathofysiologische gevolgen van (gewijzigde) DS-
domein structuren.
1.  Rho JH, Zhang W, Murali M, Roehrl MH, Wang JY: Human proteins with aﬃ  nity 
for dermatan sulfate have the propensity to become autoantigens. Am J Pathol. 
178:2177-2190, 2011
146
CHAPTER 9
Curriculum vitae 
and 
List of publications
Chapter 9
148
149
Curriculum vitae and List of publications
9
Curriculum vitae
Joost Lensen werd geboren op zaterdag 29 oktober 1977 te Venray. Na het 
behalen van zijn VWO diploma in 1996 aan het Elzendaalcollege te Boxmeer 
startt e hij in datz elfde jaar met de opleiding Bioprocestechnologie aan de 
Wageningen Agricultural University. In 1997 stapte hij over naar de studie 
Biomedische Gezondheidswetenschappen aan de Radboud Universiteit 
Nijmegen met als hoofdvakken Pathobiologie en Toxicologie. Joost heeft 
onderzoekstages gedaan op de afdelingen Psychoneurofarmacologie en 
Reumatologie  van het Universitair Medisch Centrum St. Radboud,  onder 
begeleiding van prof. dr. A.R. Cools en dr. A. Scharstuhl. In december 
2001 legde hij zijn doctoraal examen met goed gevolg af. In februari 2002 
is hij begonnen als junior onderzoeker bij de afdeling Biochemie van het 
Universitair Medisch Centrum St. Radboud aan het promotieonderzoek 
zoals beschreven in dit proefschrift onder begeleiding van dr. T.H. van 
Kuppevelt, in het kader van een NWO programmasubsidie (902-27-292). 
Sinds 2007 is hij werkzaam bij NOTOX B.V. / WIL Research Europe B.V. 
te ’s-Hertogenbosch, waar hij in opleiding is gekomen tot toxicologisch 
patholoog. In het begin van 2012 heeft hij deze opleiding succesvol afgerond 
en ontving hij de bijbehorende CRP/TP registratie als toxicologisch 
patholoog. Hij blijft werkzaam bij NOTOX B.V. / WIL Research Europe 
B.V. als toxicologisch patholoog.
Chapter 9
150
151
Curriculum vitae and List of publications
9
Curriculum vitae
Joost Lensen was born on saturday October 29, 1977 in Venray (The 
Netherlands). In 1996 he graduated from the Elzendaalcollege in Boxmeer 
(The Netherlands), after which he studied Bioprocess technology at 
the Wageningen Agricultural University. In 1997 he switched to study 
Biomedical Health Sciences at the Radboud University Nijmegen Medical 
Center, with the majors Pathobiology and Toxicology. Joost did internships 
at the departments of Psychoneuropharmacology and Rheumatology of 
the Radboud University Nijmegen Medical Center under supervision of 
prof. dr. A.R. Cools en dr. A. Scharstuhl. In December 2001 he obtained 
his Master of Science degree. In February 2002 he started a Ph.D. project 
as reported in this thesis at the department of Biochemistry at the 
Radboud University Nijmegen Medical Center under the supervision 
of dr. T.H. van Kuppevelt, made possible by a program grant (902-
27-292) from The Dutch Organization for Scientifi c Research (NWO).
Since March 2007 Joost works at NOTOX B.V. / WIL Research Europe 
B.V. in ’s-Hertogenbosch (The Netherlands), where he followed a training 
for toxicological pathologist. In the beginning of 2012 he successfully 
completed his training and became a CRP/TP registered toxicologic 
pathologist. He remains to work with NOTOX B.V. / WIL Research Europe 
B.V. as a toxicologic pathologist.
152
153
Curriculum vitae and List of publications
9
List of Publications.
1. Scharstuhl A, Diepens R, Lensen J, Vitt ers E, van Beuningen H, van der Kraan P, 
van den Berg W: Adenoviral overexpression of Smad-7 and Smad-6 diﬀ erentially 
regulates TGF-beta-mediated chondrocyte proliferation and proteoglycan synthesis. 
Osteoarthritis.Cartilage. 11:773-782, 2003
2. Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt 
TH, Berden JH: Heparan sulfate proteoglycans in glomerular infl ammation. Kidney Int 
65:768-785, 2004
3. Smeets B, Te Loeke NA, Dijkman HB, Steenbergen ML, Lensen JF, Begieneman MP, 
van Kuppevelt TH, Wetz els JF, Steenbergen EJ: The parietal epithelial cell: a key player 
in the pathogenesis of focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. J 
Am Soc Nephrol 15:928-939, 2004
4. Rops AL, van der Vlag J, Jacobs CW, Dijkman HB, Lensen JF, Wijnhoven TJ, van den 
Heuvel LP, van Kuppevelt TH, Berden JH: Isolation and characterization of conditionally 
immortalized mouse glomerular endothelial cell lines. Kidney Int 66:2193-2201, 2004
5. Lensen JF, Rops AL, Wijnhoven TJ, Hafmans T, Feitz  WF, Oosterwijk E, Banas B, Bindels 
RJ, van den Heuvel LP, van der Vlag J, Berden JH, van Kuppevelt TH: Localization 
and functional characterization of glycosaminoglycan domains in the normal human 
kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol 
16:1279-1288, 2005
6. Smits NC, Lensen JF, Wijnhoven TJ, Ten Dam GB, Jenniskens GJ, van Kuppevelt TH: 
Phage display-derived human antibodies against specifi c glycosaminoglycan epitopes. 
Methods Enzymol. 416:61-87, 2006
7. Wijnhoven TJ, Lensen JF, Rops AL, van der Vlag J, Kolset SO, Bangstad HJ, Pfeﬀ er 
P, van den Hoven MJ, Berden JH, van den Heuvel LP, van Kuppevelt TH: Aberrant 
heparan sulfate profi le in the human diabetic kidney oﬀ ers new clues for therapeutic 
glycomimetics. Am J Kidney Dis. 48:250-261, 2006
8. Lensen JF, Wijnhoven TJ, Kuik LH, Versteeg EM, Hafmans T, Rops AL, Pavao MS, 
van der Vlag J, van den Heuvel LP, Berden JH, van Kuppevelt TH: Selection and 
characterization of a unique phage display-derived antibody against dermatan sulfate. 
Matrix Biol 25:457-461, 2006
9. Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, van 
Kuppevelt T, van Goor H, van der Vlag J, Navis G, Berden JH: Induction of glomerular 
heparanase expression in rats with adriamycin nephropathy is regulated by reactive 
oxygen species and the renin-angiotensin system. J Am Soc Nephrol 17:2513-2520, 2006
10. Rops AL, Jacobs CW, Linssen PC, Boezeman JB, Lensen JF, Wijnhoven TJ, van den 
Heuvel LP, van Kuppevelt TH, van der Vlag J, Berden JH: Heparan sulfate on activated 
glomerular endothelial cells and exogenous heparinoids infl uence the rolling and 
adhesion of leucocytes. Nephrol Dial.Transplant. 22:1070-1077, 2007
154
Rops AL, van den Hoven MJ, Bakker MA, Lensen JF, Wijnhoven TJ, van den Heuvel 
LP, van Kuppevelt TH, van der Vlag J, Berden JH: Expression of glomerular heparan 
sulphate domains in murine and human lupus nephritis. Nephrol Dial.Transplant. 
22:1891-1902, 2007
Wijnhoven TJ, Lensen JF, Rops AL, McCarthy KJ, van der Vlag J, Berden JH, van den 
Heuvel LP, van Kuppevelt TH: Anti-proteinuric eﬀ ects of glycosaminoglycan-based 
drugs. Curr.Opin.Mol.Ther. 9:364-377, 2007
Wijnhoven TJ, Geelen JM, Bakker M, Lensen JF, Rops AL, Kramer AB, Navis G, van 
den Hoven MJ, van der Vlag J, Berden JH, Wetz els JF, van den Heuvel LP, Monnens 
LA, van Kuppevelt TH: Adult and paediatric patients with minimal change nephrotic 
syndrome show no major alterations in glomerular expression of sulphated heparan 
sulphate domains. Nephrol Dial.Transplant. 22:2886-2893, 2007
Rops AL, Gott e M, Baselmans MH, van den Hoven MJ, Steenbergen EJ, Lensen JF, 
Wijnhoven TJ, Cevikbas F, van den Heuvel LP, van Kuppevelt TH, Berden JH, van 
der Vlag J: Syndecan-1 defi ciency aggravates anti-glomerular basement membrane 
nephritis. Kidney Int 72:1204-1215, 2007
Rops AL, van den Hoven MJ, Baselmans MM, Lensen JF, Wijnhoven TJ, van den Heuvel 
LP, van Kuppevelt TH, Berden JH, van der Vlag J: Heparan sulfate domains on cultured 
activated glomerular endothelial cells mediate leukocyte traﬃ  cking. Kidney Int 73:52-
62, 2008
van den Hoven MJ, Wijnhoven TJ, Li JP, Zcharia E, Dijkman HB, Wismans RG, Rops 
AL, Lensen JF, van den Heuvel LP, van Kuppevelt TH, Vlodavsky I, Berden JH, van der 
Vlag J: Reduction of anionic sites in the glomerular basement membrane by heparanase 
does not lead to proteinuria. Kidney Int 73:278-287, 2008
Wijnhoven TJ, van de Westerlo EM, Smits NC, Lensen JF, Rops AL, van der Vlag J, 
Berden JH, van den Heuvel LP, van Kuppevelt TH: Characterization of anticoagulant 
heparinoids by immunoprofi ling. Glycoconj.J 25:177-185, 2008
Zmarowski A, Beekhuijzen M, Lensen J, Emmen H: Diﬀ erential performance of Wistar 
Han and Sprague Dawley rats in behavioral tests: diﬀ erences in baseline behavior and 
reactivity to positive control agents. Reprod Toxicol. 34(2):192-203, 2012
11.
12.
13.
14.
15.
16.
17.
18.
155
Dankwoord.
Zo, en dan nu het meest gelezen deel. Ik ben, zoals de meesten wel weten, 
niet iemand van heel veel woorden, maar ik zal mijn best doen om iedereen 
te bedanken. Dus om niemand te vergeten:
Bedankt allemaal!
Het heeft even geduurd maar uiteindelijk is het er dan toch van gekomen, 
het boekje is af! De afgelopen jaren, voordat dit boekje er dan eindelijk 
was, heb ik gelukkig al wel profi jt gehad van het promotieonderzoek. Het 
inlezen, bedenken en uitvoeren van onderzoek is iets wat eigenlijk iedereen 
zou moeten doen. Ook het samenwerken hoort daar bij, want uiteindelijk 
doe je het niet alleen. 
Allereerst wil ik natuurlijk mijn copromotor dr. Toin van Kuppevelt 
bedanken. Toin, bedankt voor het vertrouwen dat jij in me had om me 
aan te nemen voor dit onderzoeksproject. We zaten soms niet compleet 
op dezelfde lijn, maar uiteindelijk kwamen we er wel altijd uit, met als 
resultaat dit boekje. Dank ook voor de kundige analyse van mijn teksten, 
je suggesties waren vaak een verbetering en je hebt dan ook zeker de gift 
van de pen (helaas corrigeerde je daar ook mee wat, gecombineerd met een 
academisch handschrift, het mij wel lastiger maakte om alle wijzigingen 
door te voeren). 
Dan mijn promotoren, professor Jo Berden en professor Bert van de Heuvel. 
Jo, je bent iemand met een duidelijke mening en een grootse stem en 
persoonlijkheid. Je hebt tijdens een vliegreis naar de andere kant van de 
wereld mijn inleiding gecorrigeerd, en ik kan me zomaar voorstellen dat 
je liever een (bijna net zo goed) boek had willen lezen. Ben blij dat je voor 
de inleiding koos.
Bert, het is jammer dat we het experiment met de LC-MS niet hebben kunnen 
omvormen tot een mooi artikel, maar ik ben blij met alles wat ik daarover 
van je geleerd heb, je bijdrage aan dit boekje en onze samenwerking.
Dan de rest van de copromotoren, dr. Johan van der Vlag en dr. Angelique 
Meulemans-Rops. 
Johan, man met snor en leren jas (in mijn geheugen in ieder geval). Ik 
herinner me het ASN congres in Philadelphia, samen zitt end aan de bar in 
het hotel (met vieze Amerikaanse biertjes op tap, gelukkig hadden ze ook 
goed Nederlands spul). 
156
Angelique, de laatste tijd de motor achter het afmaken van dit boekje. 
Bedankt daarvoor! Je bent iets eerder begonnen met het onderzoeksproject 
waar we samen op zaten (en was ook iets eerder klaar….). Het was altijd 
goed samenwerken. Succes met je verdere carrière in de wetenschap, ik 
weet zeker dat het een succes wordt.
Mijn student (gedeeld met Nicole), Dr. Maartje Geraedts. Jouw hulp 
was zeer welkom bij de in vivo panning, succes met je wetenschappelijke 
carrière, waarbij je Nicole’s voorbeeld hebt gevolgd en naar de VS bent 
gegaan.
Verder met de rest van het lab, te beginnen bij: 
Elly, je weet alles van de GAG technieken en ook nog eens van de 
promovendi die voor mij het onderzoek gedaan hebben op de afdeling. Dit 
in combinatie met al jouw ervaring en hulp waren onmisbaar.
Arie, sfeermaker op de afdeling en man van de celkweek. Het was altijd 
weer leuk om naast elkaar in de celkweekruimte te zitt en en Duitse liedjes 
te zingen. 
Theo,  je was heel belangrijk voor het EM werk. Maar, het belangrijkste 
voor mij was dat ik tijdens een gesprek met jou erachter kwam dat er zoiets 
bestaat als toxicologisch patholoog. Vanzelfsprekend kende je ook nog wel 
iemand die dat was (wie ken je eigenlijk niet?) en via informatie van o.a. 
haar (Eveline) ben ik uiteindelijk in opleiding gekomen tot toxicologisch 
patholoog. Heel erg bedankt daarvoor en uiteraa rd ook voor je hulp bij de 
opmaak van dit boekje.
Via Theo gaan we uiteraard meteen door naar Paul Jap. Paul je hebt me 
enthousiast gemaakt voor de histologie. Je wist altijd weer een schat aan 
informatie uit elke coupe te halen. De microscoopsessies met jou hebben 
ervoor gezorgd dat ik door wilde gaan met histopathologisch onderzoek. 
En dan staat me ook nog iets bij over calvados uit een bekerglas….. 
En dan de man die onvermoeibaar was in ideeën spuien, Toon (mr. Q&D 
research). De tijd dat je er was op de afdeling heb ik heel veel van je geleerd 
en je enthousiasme werkte zeker aanstekelijk. 
Uiteraard wil ik ook de rest van de afdeling bedanken voor het samenwerken 
en voor de sfeer: Els (met de herkenbaarste lach), Gerdy, Willeke, Herman, 
Kaeuis, Ronnie (bedankt voor je EM werk), Guido, Marianne en Cindy.
157
En dan alle andere promovendi op de afdeling met wie het altijd gezellig 
was, zeker op AIO retraite. Het was leuk om met jullie samen onderzoek te 
doen, Nicole, Tessa, Paul, Suzan, Mieke, Peter, Gerwen en Martin. Succes 
met jullie carrières.
Leden van de manuscriptcommissie professor Wouter Feitz , professor Harry 
van Goor en dr. William Leenders, hartelijk dank voor het plaatsnemen in 
de commissie en voor het snelle beoordelen van het manuscript. 
Natuurlijk ook een dank voor al het geduld met mij aan het adres van mijn 
huidige collega’s Hett y, Ankie en Eveline; een top-team wat mij betreft. Of 
course I can’t forget our Swiss/Australian colleague and tutor Jeﬀ  and our 
recently retired colleague John; thank you for your beautiful drawing of 
the kidney in Chapter 1 (and for the coﬀ ee breaks)!
Gelukkig kon ik dankzij Blauw wit 5/6 in de weekenden al mijn frustratie 
kwijt in het voetbal, zodat ik weer fris kon beginnen op maandag. Remy 
bedankt voor je nutt ige commentaar op mijn eerste publicatie en Willem 
bedankt (?) voor het constant vragen hoe het ermee stond (nu weet je het).
Buiten het voetbal, kon ik door de week de rest van mijn energie kwijt 
tijdens het hardlopen of fi etsen met Gerco, Leon en Jouke. Met daarna 
natuurlijk samen eten inclusief een welverdiend pilsje (en steeds meer 
vrouwen en kinderen trouwens).
Uiteraard moet ik Leon (Kuik) nog wat verder bedanken. Jij bent de 
illustere naamgever van LKN1 (waar staat die N nou eigenlijk voor?), en 
mijn paranimf. Nooit gedacht dat dat bralaapje (jep, mijn eerste gedachte 
toen ik je hoorde op de gang) en ik ooit vrienden zouden worden. 
De rest van Apex Octa (Joep, Douwe, Daan, Wouter, Bastiaan en natuurlijk 
ook Frank en Wim) bedankt voor het samen voetballen, weekendjes weg, 
kerst diners en natuurlijk voor jullie vriendschap.  
Oma, ik ben nu dan eindelijk klaar met studeren. Michiel, jammer dat we 
geen gezamenlijk project hebben kunnen opzett en met jouw supermic. en 
onze GAGs. Succes met jouw promotie onderzoek!
Jan en Roelie, bedankt voor jullie belangstelling en steun en voor de 
gezelligheid in Iesselmuden.
Zo, dan ben ik nu al weer toe aan “ons pap en ons mam” en “ons Marjan” 
(en Ralf, Willemijn en Lukas). Zus, super dat jij mijn paranimf wilt zijn. 
158
Pap en mam, bedankt voor alles eigenlijk. Zonder jullie opvoeding 
en steun zou ik dit nooit hebben kunnen doen. Ik hoop dat het nu ook 
wat duidelijker is geworden wat ik nou eigenlijk gedaan heb…. (is ook 
makkelijker vertellen aan de buurt).
En dan tot slot Josine (aka skatje), al weer meer dan 12 jaar mijn steun en 
toeverlaat. Bedankt voor het bij mij zijn, en op naar de rest van ons leven 
samen! 
